<!DOCTYPE html SYSTEM "about:legacy-compat">
<html lang="en-US" class="no-js">
  <head>
    <meta charset="utf-8"/>
    <title>Chapter 18 Health Information Exchanges: Privacy and Security of Protected Health Information | Library of Maryland Regulations</title>
    <link rel="shortcut icon" href="/us/md/exec/_document/v2/images/favicons/favicon.ico"/>
    <!--Meta-->
    <meta http-equiv="X-UA-Compatible" content="IE=EDGE"/>
    <meta name="viewport" content="width=device-width, initial-scale=1"/>
    <meta name="format-detection" content="telephone=no"/>
    <meta name="HandheldFriendly" content="true"/>
    <meta itemprop="full-html" content="/us/md/exec/comar/10.25.18/index.full.html" data-document="href"/>
    <meta itemprop="toc-json" content="/us/md/exec/comar/10.25.18/index.json" data-document="href"/>
    <meta itemprop="parent-doc-url" content="/us/md/exec/comar" data-document="href"/>
    <meta itemprop="order" content="|10|25|18|"/>
    <meta itemprop="doc-type" content="container" data-document=""/>
    <meta itemprop="doc-num" content="18"/>
    <meta itemprop="ref-doc" content="Code of Maryland Regulations" data-document=""/>
    <meta itemprop="ref-path" content="10|25|18" data-document=""/>
    <!--OpenGraph-->
    <meta property="og:url" content="http://regs.maryland.gov//us/md/exec/comar/10.25.18"/>
    <meta property="og:type" content="article"/>
    <meta property="og:title" content="Chapter 18 Health Information Exchanges: Privacy and Security of Protected Health Information | Library of Maryland Regulations"/>
    <meta property="og:image" content="http://regs.maryland.gov//us/md/exec/_document/v2/images/og/og_image.png"/>
    <!--Progressive Web App-->
    <link rel="manifest" href="/manifest.json"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="apple-mobile-web-app-status-bar-style" content="#0078EF"/>
    <meta name="apple-mobile-web-app-title" content="Library of Maryland Regulations"/>
    <meta name="theme-color" content="#0078EF"/>
    <meta name="apple-mobile-web-app-capable" content="yes"/>
    <meta name="mobile-web-app-capable" content="yes"/>
    <!--PWA icons-->
    <link rel="apple-touch-icon" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="60x60" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-60x60-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="76x76" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-76x76-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="152x152" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-152x152-precomposed.png"/>
    <link rel="apple-touch-icon-precomposed" sizes="180x180" href="/us/md/exec/_document/v2/images/favicons/apple-touch-icon-180x180-precomposed.png"/>
    <link rel="mask-icon" href="/us/md/exec/_document/v2/images/favicons/safari-pinned-tab.svg" color="#0078EF"/>
    <link rel="icon" type="image/png" sizes="16x16" href="/us/md/exec/_document/v2/images/favicons/favicon-16x16.png"/>
    <link rel="icon" type="image/png" sizes="32x32" href="/us/md/exec/_document/v2/images/favicons/favicon-32x32.png"/>
    <link rel="icon" type="image/png" sizes="48x48" href="/us/md/exec/_document/v2/images/favicons/favicon-48x48.png"/>
    <!--Fonts-->
    <link href="/us/md/exec/_document/v2/biticons/biticons.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/public-sans/public-sans.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/merriweather/merriweather.css" type="text/css" rel="stylesheet" data-document=""/>
    <link href="/us/md/exec/_document/v2/fonts/roboto-mono/roboto-mono.css" type="text/css" rel="stylesheet" data-document=""/>
    <!--Document CSS-->
    <link href="/us/md/exec/_document/v2/styles/responsive.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/main.min.css" type="text/css" rel="stylesheet" media="screen" data-document=""/>
    <link href="/us/md/exec/_document/v2/styles/print.min.css" type="text/css" rel="stylesheet" media="print" data-document=""/>
    <link href="/_reader/styles/main.min.css" type="text/css" rel="stylesheet"/>
    <script src="/_reader/js/main.js" data-document=""> </script>
    <!--Links to resources that need to be prefetched-->
    <link rel="prefetch" href="/us/md/exec/comar/10.25.18/index.full.html" as="fetch"/>
    <link rel="prefetch" href="/index.json" as="fetch"/>
    <link rel="prefetch" href="/us/md/exec/comar/10.25.18/index.json" as="fetch"/>
  </head>
  <body>
    <div role="region" id="announcer" aria-live="polite" class="sr-only" aria-atomic="true" aria-label="Live messages">
      <p id="message"> </p>
    </div>
    <nav class="visually-hidden">
      <a href="#area__content" class="skip-link">Skip to main content</a>
    </nav>
    <div id="grid" class="ns__document__maryland-dsd">
      <header id="section__header" class="ns__document__maryland-dsd">
        <div id="section__header__inner" class="ns__document__maryland-dsd">
          <div id="area__logo" class="ns__document__maryland-dsd">
            <a href="/" class="logo" aria-label="Logo - Return to library home page">
              <img src="/us/md/exec/_document/v2/images/logo/logo.png" srcset="/us/md/exec/_document/v2/images/logo/logo.png 1x, /us/md/exec/_document/v2/images/logo/logo@2x.png 2x, /us/md/exec/_document/v2/images/logo/logo@3x.png 3x" alt="Library of Maryland Regulations logo"/>
            </a>
          </div>
          <div id="area__main_title" class="ns__document__maryland-dsd">
            <div class="h__library-logotype"><span class="line1">Library of</span> <span class="line2">Maryland Regulations</span></div>
          </div>
        </div>
      </header>
      <div id="section__content" class="ns__document__maryland-dsd">
        <div id="section__content__inner" class="ns__document__maryland-dsd">
          <section id="area__breadcrumbs" class="ns__document__maryland-dsd" role="region" aria-label="Breadcrumbs">
            <input type="checkbox" id="menu-trigger" class="menu-trigger" aria-label="Mobile menu toggler"/>
            <label for="menu-trigger">
              <span class="visually-hidden">Toggle mobile menu</span>
            </label>
            <nav role="navigation" aria-label="Breadcrumb navigation">
              <div class="h__ui">Navigation</div>
              <ul class="ancestors">
                <li data-search-path="library" data-search-heading="All Documents" class="no-indent">
                  <a href="/" title="Library of Maryland Regulations">Library of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations" data-search-heading="" data-search-default="true" class="li__book-open">
                  <a href="/us/md/exec/comar" title="Code of Maryland Regulations">Code of Maryland Regulations</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10" data-search-heading="">
                  <a href="/us/md/exec/comar/10" title="Title 10 MARYLAND DEPARTMENT OF HEALTH">Title 10 MARYLAND DEPARTMENT OF HEALTH</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|25" data-search-heading="">
                  <a href="/us/md/exec/comar/10.25" title="Subtitle 25 MARYLAND HEALTH CARE COMMISSION">Subtitle 25 MARYLAND HEALTH CARE COMMISSION</a>
                </li>
                <li data-search-path="library|Code of Maryland Regulations|10|25|18" data-search-heading="">
                  <span title="Chapter 18 Health Information Exchanges: Privacy and Security of Protected Health Information">Chapter 18 Health Information Exchanges: Privacy and Security of Protected Health Information</span>
                </li>
              </ul>
            </nav>
          </section>
          <main id="area__content" class="ns__document__maryland-dsd">
            <div class="h__document-title">Code of Maryland Regulations</div>
            <article class="content" role="document" data-ref-path="10|25|18">
              <div class="tuf-authenticate">
                <h1 class="h__title--small" id="/us/md/exec/comar/10.25.18">Chapter 18 Health Information Exchanges: Privacy and Security of Protected Health Information</h1>
                <section class="line-group annotations">
                  <h2>Administrative History</h2>
                  <p>Effective date: March 17, 2014 (41:5 Md. R. 344)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.01" title=".01 Scope and Purpose.">Regulation .01</a> amended as an emergency provision effective January 9, 2024 (51:3 Md. R. 152); amended permanently effective May 13, 2024 (51:9 Md. R. 440)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.01#A" title="">Regulation .01A</a>,B amended effective June 20, 2016 (43:12 Md. R. 666)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.01#B" title="">Regulation .01B</a> amended effective August 13, 2018 (45:16 Md. R. 775)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.01#B" title="">Regulation .01B</a>, E amended effective April 14, 2025 (52:7 Md. R. 322)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.01#F" title="">Regulation .01F</a> adopted effective April 14, 2025 (52:7 Md. R. 322)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.02#B" title="">Regulation .02B</a> amended effective June 20, 2016 (43:12 Md. R. 666); June 19, 2017 (44:12 Md. R. 588); August 13, 2018 (45:16 Md. R. 775); April 14, 2025 (52:7 Md. R. 322)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.02#B" title="">Regulation .02B</a> amended as an emergency provision effective January 9, 2024 (51:3 Md. R. 152); amended permanently effective May 13, 2024 (51:9 Md. R. 440)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.03" title=".03 Rights of a Health Care Consumer Concerning Information Accessed, Used, or Disclosed Through an HIE.">Regulation .03</a> amended effective June 20, 2016 (43:12 Md. R. 666); June 19, 2017 (44:12 Md. R. 588); April 14, 2025 (52:7 Md. R. 322)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.03#B" title="">Regulation .03B</a>, G amended as an emergency provision effective January 9, 2024 (51:3 Md. R. 152); amended permanently effective May 13, 2024 (51:9 Md. R. 440)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.03#D" title="">Regulation .03D</a> amended effective August 13, 2018 (45:16 Md. R. 775)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.04" title=".04 Access, Use, or Disclosure of Sensitive Health Information.">Regulation .04</a> amended effective August 13, 2018 (45:16 Md. R. 775); April 14, 2025 (52:7 Md. R. 322)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.04" title=".04 Access, Use, or Disclosure of Sensitive Health Information.">Regulation .04</a> amended as an emergency provision effective January 9, 2024 (51:3 Md. R. 152); amended permanently effective May 13, 2024 (51:9 Md. R. 440)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.05" title=".05 Requirements for Accessing, Using, or Disclosing Health Information Through an HIE.">Regulation .05</a> amended effective June 20, 2016 (43:12 Md. R. 666)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.06" title=".06 Auditing Requirements.">Regulation .06</a> amended as an emergency provision effective January 9, 2024 (51:3 Md. R. 152); amended permanently effective May 13, 2024 (51:9 Md. R. 440)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.06#A" title="">Regulation .06A</a>, F amended effective June 20, 2016 (43:12 Md. R. 666)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.07" title=".07 Remedial Actions to Be Taken by an HIE.">Regulation .07</a> amended effective June 20, 2016 (43:12 Md. R. 666)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.07#C" title="">Regulation .07C</a> amended as an emergency provision effective January 9, 2024 (51:3 Md. R. 152); amended permanently effective May 13, 2024 (51:9 Md. R. 440)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.08" title=".08 Notice of Breach and non-HIPAA Violation.">Regulation .08</a> amended effective June 19, 2017 (44:12 Md. R. 588)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.08#C" title="">Regulation .08C</a> amended effective June 20, 2016 (43:12 Md. R. 666); April 14, 2025 (52:7 Md. R. 322)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.09" title=".09 Registration and Enforcement.">Regulation .09</a> amended effective June 20, 2016 (43:12 Md. R. 666)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.09" title=".09 Registration and Enforcement.">Regulation .09</a> amended as an emergency provision effective January 9, 2024 (51:3 Md. R. 152); amended permanently effective May 13, 2024 (51:9 Md. R. 440)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.09#G" title="">Regulation .09G</a> adopted effective June 19, 2017 (44:12 Md. R. 588)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.10" title=".10 Requirements for Accessing, Using, or Disclosing of Data Through an HIE for Secondary Use.">Regulation .10</a> adopted effective June 20, 2016 (43:12 Md. R. 666)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.10" title=".10 Requirements for Accessing, Using, or Disclosing of Data Through an HIE for Secondary Use.">Regulation .10</a> amended as an emergency provision effective January 9, 2024 (51:3 Md. R. 152); amended permanently effective May 13, 2024 (51:9 Md. R. 440)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.10#A" title="">Regulation .10A</a>, B amended effective August 13, 2018 (45:16 Md. R. 775)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.10#B" title="">Regulation .10B</a> amended effective April 14, 2025 (52:7 Md. R. 322)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.11" title=".11 Requirements for Accessing, Using, or Disclosing of Data Through an HIE in an Emergency.">Regulation .11</a> adopted effective June 20, 2016 (43:12 Md. R. 666)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.11#B" title="">Regulation .11B</a> amended effective August 13, 2018 (45:16 Md. R. 775)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.11#B" title="">Regulation .11B</a> amended as an emergency provision effective January 9, 2024 (51:3 Md. R. 152); amended permanently effective May 13, 2024 (51:9 Md. R. 440)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.12" title=".12 Requirements for Providing Health Care Consumers Electronic Access to Their Health Information.">Regulation .12</a> adopted effective June 19, 2017 (44:12 Md. R. 588)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.12#A" title="">Regulation .12A</a> amended effective August 13, 2018 (45:16 Md. R. 775)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.13" title=".13 Noncontrolled Prescription Drugs Dispenser Reporting.">Regulation .13</a> adopted effective April 14, 2025 (52:7 Md. R. 322)</p>
                  <p><a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.18.14" title=".14 Operation of the State-designated HIE as a Health Data Utility.">Regulation .14</a> adopted effective April 14, 2025 (52:7 Md. R. 322)</p>
                  <h2>Authority</h2>
                  <p>Health-General Article, §§4-301, 4-302.2, 4-302.3, 4-302.5, 4-304, 19-103, 19-109(a)(1) and (8), 19-133, 19-143, and 19-145, <br/>Annotated Code of Maryland</p>
                </section>
                <h2 id="/us/md/exec/comar/10.25.18.01" data-order="|10|25|18|.01|" data-ref-path="10|25|18|.01" class="h__section">.01 Scope and Purpose.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#A">A.</span> This chapter addresses the privacy and security of protected health information maintained by a health information exchange, or obtained or released by any person through a health information exchange by adopting specific requirements:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#A(1)">(1)</span> To assure the privacy and security of protected health information accessed, used, or disclosed through a health information exchange, including protections for the secondary use of protected health information obtained, accessed, or released through a health information exchange;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#A(2)">(2)</span> To govern the access, use, maintenance, and disclosure of protected health information through or by a health information exchange;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#A(3)">(3)</span> To improve access to clinical records by treating clinicians; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#A(4)">(4)</span> To promote uses of a State-designated HIE that will assist public health agencies in reaching public health goals.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#B">B.</span> This chapter applies to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#B(1)">(1)</span> An HIE, as defined in <a class="internal-link " href="/us/md/exec/comar/10.25.18.02#B(38)" title="">Regulation .02B(38) of this chapter</a>, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#B(1)(a)">(a)</span> An individual or entity that determines, controls, or has discretion to administer any requirement, policy, or agreement that allows, enables, or requires the use of any technology or services for access, exchange, or use of electronic protected health information:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#B(1)(a)(i)">(i)</span> Among more than two unaffiliated individuals or entities that are enabled to exchange electronic protected health information with each other; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#B(1)(a)(ii)">(ii)</span> That is for a treatment, payment, or health care operations purpose, as those terms are defined in 45 CFR §164.501, regardless of whether the individuals or entities are subject to the requirements of 45 CFR Parts 160 and 164; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#B(1)(b)">(b)</span> A health information technology developer of certified health information technology as that term is defined in <a class="internal-link " href="/us/md/exec/comar/10.25.18.02#B(39)" title="">Regulation .02B(39) of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#B(2)">(2)</span> A person who accesses, uses, or discloses protected health information through an HIE;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#B(3)">(3)</span> Electronic health information stored in, or maintained by, an HIE; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#B(4)">(4)</span> A dispenser authorized by law to dispense noncontrolled prescription drugs to a patient or the patient’s agent in the State.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#C">C.</span> This chapter does not apply to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#C(1)">(1)</span> Protected health information exchanged, accessed, used, or disclosed:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#C(1)(a)">(a)</span> Between a hospital and a credentialed professional;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#C(1)(b)">(b)</span> Among credentialed professionals of a hospital’s medical staff;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#C(1)(c)">(c)</span> Between a hospital and its affiliated ancillary clinical service provider who is affiliated with the hospital and who, if required by HIPAA, has entered into a business associate agreement with the hospital;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#C(1)(d)">(d)</span> Among entities under common ownership as defined at Health-General Article, §4-301, Annotated Code of Maryland, for health care treatment, payment, or health care operations purposes, as those terms are defined in 45 CFR §164.501;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#C(1)(e)">(e)</span> By a carrier, as defined in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gin&amp;section=15-301" title="">Insurance Article, §15-301, Annotated Code of Maryland</a>, exchanging information as required by 45 CFR §156.221; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#C(1)(f)">(f)</span> Between a carrier and its business associate, as defined in 45 CFR §160.103, if the organizational and technical processes provided or governed by the business associate are transactions, as defined in 45 CFR §160.103; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#C(2)">(2)</span> The use, access, or disclosure of protected health information using point-to-point transmission unless an HIE is involved in the transmission of the data.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#D">D.</span> In the event that an HIE is unable to meet a requirement of this chapter independently, it may do so by the execution of a written agreement or by requesting an exemption in accordance with Regulation .09G or H of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E">E.</span> The requirements in this chapter are in addition to those set forth below:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E(1)">(1)</span> The Health Insurance Portability and Accountability Act of 1996, and the pertinent regulations at 45 CFR Parts 160 and 164;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E(2)">(2)</span> The Maryland Consumer Protection Act, <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gcl/gcl.pdf" title="">Commercial Law Article, Title 13, Annotated Code of Maryland</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E(3)">(3)</span> The Maryland Personal Information Protection Act, <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gcl/gcl.pdf" title="">Commercial Law Article, Title 14, Subtitle 35, Annotated Code of Maryland</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E(4)">(4)</span> The Maryland Confidentiality of Medical Records Act, Health-General Article, Title 4, Subtitle 3, Annotated Code of Maryland;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E(5)">(5)</span> Health General Article, §4-307, Annotated Code of Maryland, Confidentiality of Mental Health Records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E(6)">(6)</span> 16 CFR Part 318, Health Breach Notification Rule, adopted by the Federal Trade Commission pursuant to the HITECH Act;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E(7)">(7)</span> 42 CFR Part 2, Confidentiality of Substance Use Disorder Patient Records;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E(8)">(8)</span> Titles IV and XI of the 21st Century Cures Act and the pertinent regulations, 45 CFR Part 171, and as defined at <a class="internal-link " href="/us/md/exec/comar/10.25.18.02#B(78)" title="">Regulation .02B(78) of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#E(9)">(9)</span> All other applicable State and federal laws and regulations governing the use, access, maintenance, and disclosure of health information.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#F">F.</span> Nothing in this chapter shall prohibit:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#F(1)">(1)</span> The Maryland Department of Health, the Commission, or the Health Services Cost Review Commission from using electronic health information, subject to federal and State law, for health regulatory and public health functions;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#F(2)">(2)</span> The sharing or disclosing of information that is required to be exchanged under Health-General Article, Title 21, Subtitle 2A, Annotated Code of Maryland; or</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.01#F(3)">(3)</span> The sharing or disclosing of information that is required to be exchanged under federal law, including for the purposes of payment, as defined in 45 CFR § 164.501.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.02" data-order="|10|25|18|.02|" data-ref-path="10|25|18|.02" class="h__section">.02 Definitions.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#A">A.</span> In this chapter, the following terms have the meanings indicated.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B">B.</span> Terms Defined.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(1)">(1)</span> “Adjudication of claims” means the activities necessary for the adjudication or subrogation of a health benefit claim that has been filed or may be filed by a patient, or with the authorization of a patient on the patient’s behalf, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(1)(a)">(a)</span> Determinations of eligibility or coverage, including coordination of benefits or the determination of cost-sharing amounts;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(1)(b)">(b)</span> Reasonable prospective, concurrent, or retrospective utilization review or predetermination of benefit coverage;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(1)(c)">(c)</span> Review, audit, and investigation of a specific claim for payment of benefits with respect to medical necessity, coverage under a health plan, appropriateness of care, or justification of charges;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(1)(d)">(d)</span> Billing, claims management, collection activities, obtaining payment under a contract for reinsurance, and related health care data processing; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(1)(e)">(e)</span> Risk adjustments based on enrollee health status and demographic characteristics.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(2)">(2)</span> “Ancillary clinical service provider” means a health care provider who has a direct contractual agreement with the hospital to provide therapeutic, diagnostic, or custodial ancillary services for the hospital as part of its affiliation. Ancillary services may include skilled nursing, home care, outpatient rehabilitation and therapy, transportation, ambulatory surgery, dialysis, laboratory, radiology, pharmacy, and chemotherapy.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(3)">(3)</span> “Application Programming Interface” or “API” has the same meaning as ‘Certified API Technology’ as stated at 45 CFR § 170.404.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)">(4)</span> “Appropriate notice to one or more health care consumers” means notice, related to a request for individually identifiable health information for secondary use, that meets the following requirements:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(a)">(a)</span> The notice:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(a)(i)">(i)</span> Must include educational information pertaining to the requesting entity's secondary use of data obtained through an HIE, including why the entity is requesting the data and how it intends to use the data;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(a)(ii)">(ii)</span> May describe an ongoing scenario such as care coordination or other ongoing care management activities against which subsequent data may be requested by the care management organization from the HIE; in such cases, the potential need for and nature of such requests shall be included in the description of the initial request to the external review board and shall be plainly documented in the notice to health care consumers;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(a)(iii)">(iii)</span> Must include a clear and detailed description of the steps a health care consumer must take in order to grant authorization for the use of their information or to deny authorization;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(a)(iv)">(iv)</span> Must provide clear, detailed notice that the health care consumer's failure to respond could result in their information being disclosed without their authorization, if an independent external review committee waives authorization; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(a)(v)">(v)</span> Must have characteristics detailed in Regulation .03B(2)(b)—(g) of this chapter.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(b)">(b)</span> The care management organization, or its third party, has provided to each health care consumer whose identifiable information is being requested:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(b)(i)">(i)</span> Notice as described above, using varied methods, where possible, to reach the health care consumer;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(b)(ii)">(ii)</span> The opportunity to submit authorization or denial of authorization through various methods such as email, online, mail, and phone; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(4)(b)(iii)">(iii)</span> At least 30 calendar days from the time of the first notice to respond to the notice.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(5)">(5)</span> “Authentication” means the process of establishing confidence in user identities electronically presented to an information system.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(6)">(6)</span> “Authorization” has the meaning provided in 45 CFR §164.508.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(7)">(7)</span> “Authorized purpose” means the specific reason consistent with this chapter and State and federal law for which an authorized user may use, access, or disclose protected health information through or from an HIE. The authorized purpose may include daily operations and maintenance of the HIE for:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(7)(a)">(a)</span> The staff of the HIE who has signed a confidentiality and nondisclosure agreement; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(7)(b)">(b)</span> The staff of the HIE's contractor if the contractor:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(7)(b)(i)">(i)</span> Has entered into a business associate agreement with the HIE; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(7)(b)(ii)">(ii)</span> Has contractually agreed to limit access to the HIE only to its employees, agents, and independent contractors with a need-to-know; and who are under a confidentiality restriction, which may include a binding work force policy and procedure.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(8)">(8)</span> “Authorized user” means an individual identified by a participating organization or a health information exchange, including a health care consumer, who may use, access, or disclose protected health information through or from a health information exchange for a specific authorized purpose and whose HIE access is not currently suspended or terminated under Regulation .05, .07, or .09 of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(9)">(9)</span> “Breach” has the meaning provided in 45 CFR §164.402.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(10)">(10)</span> “Business associate” has the meaning provided in 45 CFR §160.103.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(11)">(11)</span> “Business day” means any day except Saturday, Sunday, or a holiday on which State offices are closed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(12)">(12)</span> “Care management organization”, in the context of secondary use, means any entity that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(12)(a)">(a)</span> Has a financial or specific care-related responsibilities for individuals with whom they may not have a treatment, payment, or health care operations relationship under 45 CFR §164.501(1); and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(12)(b)">(b)</span> Has the legal or regulatory authority to exercise the responsibilities stated in <a class="internal-link " href="/us/md/exec/comar/10.25.18.02#B(12)(a)" title="">§B(12)(a) of this regulation</a>; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(12)(c)">(c)</span> Is operating in accordance with Maryland's All-Payer Model or successor agreement between the Centers for Medicare and Medicaid Services and the State of Maryland;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(12)(d)">(d)</span> Does not include a third-party entity engaged by a participating organization to provide care management services on behalf of such participating organization for a primary use.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(13)">(13)</span> “Commission” means the Maryland Health Care Commission.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(14)">(14)</span> “Consent management application” means a software tool or platform designed to request, receive, store, and manage a person in interest’s consent preferences regarding the sharing of the patient’s electronic health information through an HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(15)">(15)</span> “Control” means providing a method by which the health care consumer can electronically provide instructions to an HIE regarding the disclosure of the patient's information being made available through the HIE, which may include specifying:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(15)(a)">(a)</span> The individuals and organizations to whom the HIE may disclose the patient's health information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(15)(b)">(b)</span> The circumstances (e.g., all, emergency only, inpatient, etc.) under which the patient's health information may be disclosed through the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(15)(c)">(c)</span> What type of health information may be disclosed, such as prescription history, laboratory reports, hospital encounters, and to whom.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(16)">(16)</span> “Core elements of the Master Patient Index (MPI)” are the minimum elements that are required for an HIE to identify a particular patient across separate clinical, financial, and administrative systems, as needed for exchanging health information electronically.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(17)">(17)</span> “Core HIE education content” means the educational information developed and approved by the Maryland Health Care Commission, after consultation with interested parties, and includes a general overview of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(17)(a)">(a)</span> The fundamentals of health information technology, including electronic health records and the exchange of electronic health information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(17)(b)">(b)</span> Health information privacy and security laws; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(17)(c)">(c)</span> The benefits and risks to patients of exchanging health information through an HIE as compared to opting-out and exchanging health information through a paper-based system.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(18)">(18)</span> “Covered entity"” has the meaning provided in 45 CFR §160.103.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(19)">(19)</span> “Credentialed professional” means an individual who has been credentialed by a hospital to provide clinical services to patients of the hospital. Credentialing includes the formal evaluation and verification of an individual's necessary qualifications, education, training, and professional license if applicable, through the collection, verification, and evaluation of data relevant to the individual's professional performance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(20)">(20)</span> “Data use agreement” means an agreement that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(20)(a)">(a)</span> Is entered into by an HIE and an entity receiving data for secondary data use purposes, regardless of whether or not the entity is a covered entity as defined by HIPAA; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(20)(b)">(b)</span> Requires:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(20)(b)(i)">(i)</span> The receiving entity to accept and comply with the requirements in this chapter and, to the extent the receiving entity meets the definition of a business associate under HIPAA, current State and federal laws pertaining to business associates and business associate agreements;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(20)(b)(ii)">(ii)</span> Both parties to access, transmit, and protect the PHI in accordance with current legal requirements and industry standards and practices;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(20)(b)(iii)">(iii)</span> The receiving entity to destroy the PHI, including back-up and archived copies of the PHI, in accordance with industry standards and practices, when the purposes for which it has been requested are completed, unless retention of the PHI is otherwise required by law; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(20)(b)(iv)">(iv)</span> The receiving entity not to reuse or disclose the PHI to any person or organization, except as required or permitted by law; or if disclosed to a third party, which will act on behalf of the receiving entity, the third party and the receiving entity enter a contractual agreement that requires the third party to be bound by the provisions of the data use agreement that applies to the receiving entity.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(21)">(21)</span> “De-identified data” means health information that neither identifies nor provides a reasonable basis to identify an individual and that meets the standards and specifications provided in 45 CFR §164.514(a)—(b).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(22)">(22)</span> “Disclose” or “disclosure” means the release, redisclosure, transfer, provision, access, transmission, communication, or divulgence in any other manner of health information, including an acknowledgment that a health record on a particular patient or recipient exists, outside the entity holding the information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(23)">(23)</span> “Dispense” has the meaning stated in <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12" title="">Health Occupations Article, §12</a>–101, Annotated Code of Maryland, but does not include giving a patient prescription drug samples in accordance with <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=12-102" title="">Health Occupations Article, §12-102(d), Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(24)">(24)</span> Dispenser.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(24)(a)">(a)</span> “Dispenser” means a person authorized by law to dispense a noncontrolled prescription drug to a patient or a patient’s agent in the State, including a nonresident pharmacy so authorized.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(24)(b)">(b)</span> “Dispenser” does not include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(24)(b)(i)">(i)</span> A licensed hospital pharmacy that only dispenses a monitored prescription drug for direct administration to an inpatient of the hospital;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(24)(b)(ii)">(ii)</span> An opioid treatment services program, as defined by <a class="internal-link no-wrap" href="/us/md/exec/comar/10.47.07.02" title=".02 Definitions.">COMAR 10.47.07.02</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(24)(b)(iii)">(iii)</span> A veterinarian licensed under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gag/gag.pdf" title="">Agriculture Article, Title 2, Subtitle 3, Annotated Code of Maryland</a>;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(24)(b)(iv)">(iv)</span> A pharmacy issued a waiver permit under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.34.17.03" title=".03 Requirements of a Waiver Pharmacy.">COMAR 10.34.17.03</a> that provides pharmaceutical specialty services exclusively to persons living in assisted living facilities, comprehensive care facilities, and developmental disabilities facilities; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(24)(b)(v)">(v)</span> A pharmacy issued a waiver by the Department under <a class="internal-link no-wrap" href="/us/md/exec/comar/10.47.07.03#G" title="">COMAR 10.47.07.03G</a> from reporting dispensing to hospice patients.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(25)">(25)</span> “Download” means providing a method by which the health care consumer can obtain an electronic copy of the patient's information that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(25)(a)">(a)</span> Is in a readily available industry standard format; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(25)(b)">(b)</span> Allows the health care consumer to save, maintain, use, or transmit the patient's information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(26)">(26)</span> “Electronic health care transactions” means transactions, as defined by 45 CFR § 160.103, that meet the specifications of 45 CFR § 162.920.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(27)">(27)</span> “Electronic health information” means health information that is in an electronic form.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(28)">(28)</span> “Electronic health record” or “EHR” means an electronic record of health-related information on an individual that includes patient demographic and clinical health information that may be used for clinical diagnosis, treatment, improvement of health care quality, and patient care.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(29)">(29)</span> “Electronic health record system” means technology that electronically captures, manages, and organizes health records and may have the capacity to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(29)(a)">(a)</span> Provide clinical decision support;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(29)(b)">(b)</span> Support physician order entry;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(29)(c)">(c)</span> Capture and query information relevant to health care quality; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(29)(d)">(d)</span> Exchange electronic health information with and integrate the information from other sources.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(30)">(30)</span> “Emergency” has the meaning provided in Health-General Article, §4-301(d), Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(31)">(31)</span> “External and independent review committee” means a group of individuals that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(31)(a)">(a)</span> Is responsible for reviewing and making a determination regarding a request for a waiver of authorization related to population health management; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(31)(b)">(b)</span> Shall be minimally composed of:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(31)(b)(i)">(i)</span> At least three health care consumer members, three health care provider members, one member representing the scientific community, one member with privacy and legal expertise, and one member with HIE expertise;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(31)(b)(ii)">(ii)</span> Members who have appropriate professional competencies necessary to review the request; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(31)(b)(iii)">(iii)</span> More than half of the members are not affiliated with or related to any person affiliated with the requesting entity and are free from any conflicts of interest with the requesting entity.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(32)">(32)</span> “Federalwide assurance” or "FWA" means an agreement between an entity and the United States Department of Health and Human Services under which the entity agrees to comply with:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(32)(a)">(a)</span> Federal regulations concerning research involving human subjects;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(32)(b)">(b)</span> Department of Health and Human Services regulations found at 45 CFR Part 46;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(32)(c)">(c)</span> A statement of principles governing the entity in the discharge of its responsibilities for protecting the rights and welfare of human subjects of research conducted at or sponsored by the entity; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(32)(d)">(d)</span> Other requirements of the agreement.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(33)">(33)</span> “Granular patient consent” means expressed preferences made by a health care consumer regarding the disclosure, access, and use of the patient's protected health information according to the type of information, type of provider, purpose, or circumstance communicated by the health care consumer to the HIE through reasonable means specified by the HIE, which shall include paper and electronic means.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(34)">(34)</span> “Health care” has the meaning provided in Health-General Article, §4-301(g), Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(35)">(35)</span> “Health care consumer” or “consumer” means a recipient, a patient, or a person in interest, as defined in this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(36)">(36)</span> “Health care provider” has the meaning provided in Health-General Article, §4-301(h), Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(37)">(37)</span> “Health Data Utility” means an HIE that operates for the following purposes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(37)(a)">(a)</span> The collection, aggregation, and analysis of clinical information, public health data, and electronic administrative health care transactions;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(37)(b)">(b)</span> The communication of data between public health officials and health care providers to advance disease control and health equity; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(37)(c)">(c)</span> The enhancement and acceleration of interoperability of health information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(38)">(38)</span> “Health information” means any information, whether oral or recorded in any form or medium, including electronic health information, that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(38)(a)">(a)</span> Is created or received by a health care provider, health plan, public health authority, employer, life insurer, school or university, or health care clearinghouse; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(38)(b)">(b)</span> Relates to the past, present, or future physical or mental health or condition of an individual, the provision of health care to an individual, or the past, present, or future payment for the provision of health care to an individual.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(39)">(39)</span> “Health information exchange” or “HIE” has the meaning provided in Health-General Article §4-301(i), Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(40)">(40)</span> “Health information technology developer of certified health information technology” or “developer” means an entity that develops, sells, licenses, provides, or offers health information technology, as defined in 42 U.S.C. 300jj(5), to persons in the State and has one or more health information technology modules certified under a program that is kept or recognized by the National Coordinator in accordance with 42 U.S.C. 300jj-11(c)(5).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(41)">(41)</span> Health Record.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(41)(a)">(a)</span> “Health record” means any health information, in any form or medium, created or transmitted by a participating organization or health care consumer that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(41)(a)(i)">(i)</span> Is entered in the record of a patient or recipient; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(41)(a)(ii)">(ii)</span> Identifies or can readily be associated with the identity of a patient or a recipient.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(41)(b)">(b)</span> “Health record” includes a medical record as defined in Health-General §4-301(k), Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(42)">(42)</span> “HIE access matrix” means a document that is used by a participating organization to assign access to each authorized user and describes the type of protected health information (including, but not limited to, lab reports, prescription drug information, prior admissions to hospitals), that each authorized user is allowed to retrieve from an HIE. An HIE access matrix may specify a use case (including but not limited to electronic eligibility, clinical lab ordering/results delivery, electronic prescribing, medication history, clinical summary exchange, and other items) and corresponding associated data, including identified sensitive health information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(43)">(43)</span> “HIPAA” means the Health Insurance Portability and Accountability Act of 1996, P.L.104191, as amended, and the implementing regulations at 45 CFR Parts 160 and 164, as amended, and including as amended by the HITECH Act.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(44)">(44)</span> “HITECH Act” mean the Health Information Technology for Economic and Clinical Health Act, Title XIII of Division A and Title IV of Division B of the American Recovery and Reinvestment Act of 2009 (Pub. L. 111-5), as amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(45)">(45)</span> “Hospital” has the meaning provided in Health-General Article, §19-301(f), Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(46)">(46)</span> “Improvement of patient safety” means actions, strategies, or protocols to prevent health care errors, enhance the quality of care, and ensure a safe health care environment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(47)">(47)</span> “Individually identifiable health information” has the meaning provided in 45 CFR §160.103 and includes any health information that contains personal identifiers, as detailed in 45 CFR §164.514(b).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(48)">(48)</span> “Institutional Review Board” or “IRB” means a committee or other group designated by an institution or affiliated with a State agency that performs a review of proposed research that has:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(48)(a)">(a)</span> Registered with the Office of Human Research Protections Electronic Submission System; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(48)(b)">(b)</span> Obtained FWA approval from the Office of Human Research Protections.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(49)">(49)</span> “Interoperability” has the meaning provided in 45 CFR §170.102.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(50)">(50)</span> “Legally protected health information” means the health information with a date of service after May 31, 2022, that is subject to restrictions under Health-General Article, §4-302.5, Annotated Code of Maryland, and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.11.08" title="Chapter 08 Abortion Care Disclosure">COMAR 10.11.08</a>, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(50)(a)">(a)</span> Mifepristone data, as defined by the Secretary; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(50)(b)">(b)</span> As specified by the Secretary, the diagnosis, procedure, medication, and other codes related to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(50)(b)(i)">(i)</span> Abortion care; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(50)(b)(ii)">(ii)</span> Sensitive health services, as defined by Health-General, §4-301, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(51)">(51)</span> “Master patient index” or “MPI” means a database that maintains a unique index identifier for each patient whose protected health information may be accessible through an HIE and is used to cross reference patient identifiers across multiple participating organizations to allow for patient search, patient matching, and consolidation of duplicate records.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(52)">(52)</span> “MHCC” or the “Commission” means the Maryland Health Care Commission.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(53)">(53)</span> “Nationally recognized standards” means technical standards for the exchange, integration, sharing, or retrieval of electronic health information considered reliable by the health IT industry nationally.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(54)">(54)</span> “Noncontrolled Prescription Drugs” means a prescription drug, as defined in the <a class="internal-link " href="https://mgaleg.maryland.gov/mgawebsite/laws/StatuteText?article=gho&amp;section=21" title="">Health Occupations Article § 21 </a>201, that is not a controlled dangerous substance designated under <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gcr/gcr.pdf" title="">Criminal Law Article, Title 5, Subtitle 4, Annotated Code of Maryland</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(55)">(55)</span> “Non-HIPAA violation” means an inappropriate use, access, maintenance, or disclosure of health information that is not a HIPAA violation, but is inconsistent with State or federal law or this chapter, including a violation of 42 CFR Part 2.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)">(56)</span> “Notice” (or “notify” or “notification”) means an action that is required to be taken in writing or by written request under this chapter by a person, including an HIE, a health care consumer, a participating organization, or the Commission, in order to provide information to another that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)(a)">(a)</span> Is sent by letter delivered to the person's address of record;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)(b)">(b)</span> Uses one of the following electronic or digital mechanisms where the delivery is acknowledged or confirmed:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)(b)(i)">(i)</span> An email, when the receiving person has provided an email address;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)(b)(ii)">(ii)</span> By a health care consumer using the receiver's website; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)(b)(iii)">(iii)</span> By a health care consumer using a patient portal;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)(c)">(c)</span> By a health care consumer using telephonic or similar method, provided that a written confirmation of the conversation is provided to the health care consumer by the person receiving the notification or request by the following means:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)(c)(i)">(i)</span> An email, when the health care consumer has provided an email address and delivery is acknowledged or confirmed; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)(c)(ii)">(ii)</span> A letter delivered to the health care consumer's address of record; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(56)(d)">(d)</span> Complies with HIPAA and all other applicable federal and State laws and regulations.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(57)">(57)</span> “Opt out” means the explicit written notice by a health care consumer to an HIE or through the consent management application that the patient has elected not to participate in the HIE, so that the HIE shall not disclose such patient's protected health information, or data derived from such patient's health information, except as consistent with this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(58)">(58)</span> “Part 2” means the federal Confidentiality of Substance Use Disorder Patient Records regulations found in 42 CFR Part 2 and supplemented by the final rule 82 FR 6052.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(59)">(59)</span> “Part 2 information” means any information subject to the regulations under 42 CFR Part 2.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(60)">(60)</span> “Participating organization” means a covered entity that enters into an agreement with an HIE that governs the terms and conditions under which its authorized users may use, access, or disclose protected health information through the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(61)">(61)</span> “Patient” means an individual who receives health care and on whom a medical record is maintained.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(62)">(62)</span> “Payor” means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(62)(a)">(a)</span> An insurer that holds a certificate of authority in the State and provides health benefit plans in the State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(62)(b)">(b)</span> A health maintenance organization that holds a certificate of authority in the State;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(62)(c)">(c)</span> A managed care organization authorized to receive Medicaid prepaid capitation payments under Health-General Article, Title 15, Subtitle 1, Annotated Code of Maryland; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(62)(d)">(d)</span> A nonprofit health service plan that holds a certificate of authority in the State.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(63)">(63)</span> “Person” means an individual, trust or estate, general or limited partnership, joint stock company, unincorporated association or society, municipal or other corporation, incorporated association, limited liability partnership, limited liability company, the State, an agency or political subdivision of the State, a court, and any other governmental entity.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)">(64)</span> “Person in interest” means any of the following, but does not include a participating organization:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(a)">(a)</span> An adult on whom a health care provider maintains a medical record;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(b)">(b)</span> A person authorized to consent to health care for an adult consistent with the authority granted, including without limitation, a guardian, surrogate, or person with a medical power of attorney;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(c)">(c)</span> A duly appointed personal representative of a deceased person;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(d)">(d)</span> Either:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(d)(i)">(i)</span> A minor, if the medical record concerns treatment to which the minor has the right to consent and has consented under Title 20, Subtitle 1 of the Health-General Article, Annotated Code of Maryland; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(d)(ii)">(ii)</span> A parent, guardian, custodian, or a representative of the minor designated by a court, in the discretion of the attending physician who provided the treatment to the minor, as provided in Health-General Article, §§20 -102 and 20-104, Annotated Code of Maryland; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(e)">(e)</span> If §B(55)(d) of this regulation does not apply to a minor:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(e)(i)">(i)</span> A parent of the minor, except if the parent's authority to consent to health care for the minor has been specifically limited by a court order or a valid separation agreement entered into by the parents of the minor; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(e)(ii)">(ii)</span> A person authorized to consent to health care for the minor consistent with the authority granted; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(64)(f)">(f)</span> An attorney appointed in writing by a person listed in this definition regarding matters subject to this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(65)">(65)</span> “Point-to-point transmission” means a secure electronic transmission of PHI, including, but not limited to, records sent via facsimile or secure clinical messaging service, sent by a single entity that can be read only by the single receiving entity designated by the sender. A point-to-point transmission may be facilitated by an HIE and mirrors a paper-based exchange, such as a referral to a specialist, a discharge summary sent to where the patient is transferred, lab results sent to the practitioner who ordered them, or clinical information sent from a hospital to the patient's health plan for quality improvement or care management/coordination activities for such patient.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(66)">(66)</span> “Population health management purpose” means the use of data, for secondary use, available from or through an HIE for population-based activities relating to the improvement of patient and population health or the reduction of health care costs, including but not limited to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(66)(a)">(a)</span> Patient outreach activities that involve care management;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(66)(b)">(b)</span> Development or assessment of, quality indicators, patient patterns or outcomes, or support of quality reporting;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(66)(c)">(c)</span> Development and evaluation of innovative care delivery models and programs; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(66)(d)">(d)</span> Risk assessment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(67)">(67)</span> “Primary use of HIE data” or “primary use” means use and disclosure of data accessed, used, or disclosed through an HIE for purposes of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(67)(a)">(a)</span> Treatment as defined by HIPAA;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(67)(b)">(b)</span> Payment as defined by HIPAA;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(67)(c)">(c)</span> Reporting to public health authorities in compliance with reporting required or permitted by law;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(67)(d)">(d)</span> Other uses or disclosures required or permitted by law and in accordance with this chapter, including those set forth in Health-General Article, §4-305(b), Annotated Code of Maryland; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(67)(e)">(e)</span> Health care operations, as defined by HIPAA, for conducting quality assessment and improvement activities, including outcomes evaluation and development of clinical guidelines, provided that the obtaining of generalizable knowledge is not the primary purpose of any studies resulting from such activities.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(68)">(68)</span> “Privacy board” means a group of individuals that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(68)(a)">(a)</span> Is responsible for reviewing and making a determination on a request for secondary data for research purposes;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(68)(b)">(b)</span> Has the authority consistent with 45 CFR §164.512, including approval of a waiver or alteration of authorization requirement;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(68)(c)">(c)</span> Is designated or convened by the HIE, which may establish guidelines concerning a quorum;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(68)(d)">(d)</span> Shall meet the member composition requirements detailed in 45 CFR §164.512(i)(1)(i)(B)(1) and (3); and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(68)(e)">(e)</span> Shall assure that less than half of its members considering a request are affiliated with or related to any person affiliated with the requesting entity.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(69)">(69)</span> “Protected health information” or “PHI” a subset of health information, means:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(69)(a)">(a)</span> Protected health information as defined in 45 CFR §160.103; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(69)(b)">(b)</span> A medical record as defined in the Health-General Article, §4-301(i); and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(69)(c)">(c)</span> Includes sensitive health information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(70)">(70)</span> “Public health authority” has the meaning provided in 45 CFR §164.501.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(71)">(71)</span> “Qualified research organization” means an entity that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(71)(a)">(a)</span> Has entered into a data use agreement with the HIE from which data is being requested;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(71)(b)">(b)</span> Is determined, by an IRB or privacy board, to have expertise to carry out research specific to its request;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(71)(c)">(c)</span> Is determined, by an IRB or privacy board, to have a legitimate and credible reason or obligation to carry out research specific to its request; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(71)(d)">(d)</span> Is a participating organization, public health authority, or is engaged in joint research with a participating organization or public health authority.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(72)">(72)</span> “Query” means to electronically search for information available through an HIE using the services provided by the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(73)">(73)</span> “Research” means the use of secondary data available from or through an HIE for the systematic investigation, including research development, testing, preparation, and evaluation, designed to develop or contribute to generalizable knowledge as defined in 45 CFR §164.501 and 45 CFR §46.102, including the use of de-identified data and limited data sets.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(74)">(74)</span> “Secondary use of HIE data” or “secondary use” means any use or disclosure of data accessed, used or disclosed through an HIE that is not a primary use. Examples of secondary use include, but are not limited to, use of HIE data for conducting research, improving patient safety, marketing, or the sale of HIE data.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(75)">(75)</span> “Secretary” means the Secretary of Health.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(76)">(76)</span> “Sensitive health information” means a subset of PHI, which consists of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(76)(a)">(a)</span> Part 2 information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(76)(b)">(b)</span> Legally protected health information; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(76)(c)">(c)</span> Any other information that has specific legal protections in addition to those required under HIPAA or the Maryland Confidentiality of Medical Records Act.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(77)">(77)</span> “State-designated HIE” means an HIE designated by the Maryland Health Care Commission and the Health Services Cost Review Commission pursuant to the statutory authority set forth under Health-General Article, §19-143, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(78)">(78)</span> “State health improvement program” means a State initiative designed to enhance public health through strategic planning, targeted interventions, and collaboration with stakeholders and the federal government, including State efforts in support of the Total Cost of Care model and successor models agreed to by the federal government and the State.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(79)">(79)</span> “Submit”, when used in reference to consumer-submitted data, means providing a method by which the health care consumer can electronically upload information to the HIE to then be made available to authorized users of the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(80)">(80)</span> “System administrator” means an individual employee within a participating organization (or an individual employed by a contractor to the participating organization) who is designated by the participating organization to manage the user accounts of specified individuals within the participating organization in coordination with an HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(81)">(81)</span> “Third party system” means hardware or software provided by an external entity to a participating organization, which interoperates with an HIE to allow an authorized user access to information through the HIE and may include an electronic health record system.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(82)">(82)</span> “21st Century Cures Act” means the 21st Century Cures Act, P.L. 114-255, as amended, and the pertinent regulations at 45 CFR Parts 156, 170, and 171 and 42 CFR Parts 422, 431, 438, 457, 482, and 485.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(83)">(83)</span> “Unusual finding” means an irregularity in the manner in which use, access, maintenance, disclosure, or modification of health information or sensitive health information transmitted to or through an HIE should occur that could give rise to a breach, a violation under this chapter or a violation of other applicable privacy or security laws.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(84)">(84)</span> “Use” has the meaning provided in 45 CFR §160.103.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.02#B(85)">(85)</span> “User accounts” mean the records associated with an authorized user's credentials and activities with an HIE or a third party system.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.03" data-order="|10|25|18|.03|" data-ref-path="10|25|18|.03" class="h__section">.03 Rights of a Health Care Consumer Concerning Information Accessed, Used, or Disclosed Through an HIE.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A">A.</span> A health care consumer has the following rights in accordance with the requirements specified in this section:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(1)">(1)</span> The right to have information regarding the health care consumer's rights under these regulations readily available to assist the health care consumer in making an informed decision concerning:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(1)(a)">(a)</span> The accessibility of a patient's protected health information electronically through an HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(1)(b)">(b)</span> The risks and benefits of participating in the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)">(2)</span> The right to opt out of an HIE.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)(a)">(a)</span> A health care consumer has the right to opt out of an HIE at any time and refuse access to the patient's PHI through an HIE, except when a disclosure is limited to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)(a)(i)">(i)</span> Core elements of the MPI;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)(a)(ii)">(ii)</span> A disclosure that a person is required to make under federal or State law requirements;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)(a)(iii)">(iii)</span> Results of a diagnostic procedure sent to the health care provider who ordered the procedure or another provider as designated by the ordering provider as part of the care delivery of a patient;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)(a)(iv)">(iv)</span> Information regarding prescription medications dispensed or filled by a pharmacy, sent to the health care provider who ordered the prescriptions or another health care provider as designated by the ordering health care provider;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)(a)(v)">(v)</span> Public health authorities for reporting purposes required, authorized, or otherwise compliant with applicable law; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)(a)(vi)">(vi)</span> Communications permitted under HIPAA or State law without a health care consumer's consent or authorization when using point-to-point.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)(b)">(b)</span> Provided, however, that §A(2)(a)(iii), (iv), and (vi) of this regulation shall not apply to disclosures of sensitive health information, which receive additional protections consistent with <a class="internal-link " href="/us/md/exec/comar/10.25.18.04" title=".04 Access, Use, or Disclosure of Sensitive Health Information.">Regulation .04 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(2)(c)">(c)</span> A health care consumer shall be advised in writing by the HIE receiving the opt-out notice or request that opting out does not preclude any participating organization that has received or accessed PHI via the HIE prior to such opt-out, and incorporated such PHI into its records, from retaining such information in its records.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(3)">(3)</span> An HIE shall make a good faith effort to facilitate a health care consumer's amendment of the patient's health information available through the HIE by informing the health care consumer how to seek amendment of the information.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(3)(a)">(a)</span> An HIE shall send information regarding the process for amending health information being made available through the HIE within 20 days of receiving notice from a health care consumer of a desire to amend the patient's health information available through the HIE and shall include the contact information of relevant participating organizations that provided the information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(3)(b)">(b)</span> This process shall be in accordance with the requirements specified in Health-General Article, §4-304(b), Annotated Code of Maryland and HIPAA, including 45 CFR §164.526.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(3)(c)">(c)</span> An HIE shall make a good faith effort to notify the participating organization of each authorized user who has accessed, used, or disclosed the health information that has subsequently been amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#A(4)">(4)</span> The right to resume participation in an HIE after previously opting out in accordance with these regulations. Any such resumption of participation shall be upon written notice or request by the health care consumer.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B">B.</span> An HIE shall provide needed information about the HIE to a health care consumer whose protected health information is maintained by a health information exchange, or may be accessed, used, or disclosed through the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)">(1)</span> An HIE shall develop, adopt, implement, and keep current a health care consumer education plan that considers stakeholder input.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(a)">(a)</span> The health care consumer education plan shall include the core HIE education content as defined in <a class="internal-link " href="/us/md/exec/comar/10.25.18.02" title=".02 Definitions.">Regulation .02 of this chapter</a>.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(b)">(b)</span> The health care consumer education plan shall outline how the HIE will make available the following information to health care consumers:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(b)(i)">(i)</span> A description of each type of patient health information that may be used, accessed or disclosed through the HIE;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(b)(ii)">(ii)</span> The health information maintained by the HIE;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(b)(iii)">(iii)</span> The specific details concerning who may access, use, or disclose a patient's health information and for what purpose;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(b)(iv)">(iv)</span> The privacy and security measures that the HIE has implemented to protect health information, and a detailed explanation of what happens if there is a breach that results in unauthorized access to protected health information;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(b)(v)">(v)</span> A health care consumer's rights regarding the HIE and the control over, protection of, use of, and correction of each type of health information;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(b)(vi)">(vi)</span> The process provided for a health care consumer to exercise the health care consumer's rights, including a detailed description of the steps a health care consumer needs to take in order to opt out from participation in the HIE;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(b)(vii)">(vii)</span> The implications of a health care consumer's decision to opt out of participation in an HIE and not permit the disclosure of that consumer's PHI to authorized users, except as otherwise permitted under applicable law; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(1)(b)(viii)">(viii)</span> The HIE's policies and procedures, including without limitation, policies and procedures consistent with these regulations regarding how the health care consumer may gain access to the patient's health information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(2)">(2)</span> An HIE shall develop and implement health care consumer education materials as provided in <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#B(1)" title="">§B(1) of this regulation</a>. Such education materials shall have the following characteristics:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(2)(a)">(a)</span> Provide a balanced perspective, outlining the various points of view concerning each subject matter, including the risks and benefits associated with sharing protected health information electronically through the HIE;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(2)(b)">(b)</span> Are not inaccurate or misleading;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(2)(c)">(c)</span> Minimize the use of technical terms and, when such terms are necessary, clearly define the technical terms;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(2)(d)">(d)</span> Use plain language that is easily understandable to each health care consumer population served, taking into account the various levels of education, understanding, and interest across that population;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(2)(e)">(e)</span> Use text and illustrations that are culturally sensitive, language appropriate, and that recognize user diversity including ethnicity, age, race, and gender;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(2)(f)">(f)</span> Update material to include and incorporate new information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(2)(g)">(g)</span> Specify the time sensitivity of any material included.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(3)">(3)</span> An HIE shall cooperate with applicable State agencies to educate health care consumers consistent with a statewide education plan approved by such applicable State agency.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(4)">(4)</span> An HIE shall make health care consumer educational materials readily available, at no charge, to participating organizations and the participating organizations’ users through distribution channels such as websites, postal mail, email, secure third-party smart phone applications, and any other reasonable media or distribution channel commonly used and generally available to the HIE and health care consumer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(5)">(5)</span> In addition to the foregoing requirements, with regard to sensitive health information, the health care consumer educational content shall include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(5)(a)">(a)</span> The scope of sensitive health information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(5)(b)">(b)</span> The health care consumer’s right to control sensitive health information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(5)(c)">(c)</span> The method by which to engage in the granular patient consent process;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(5)(d)">(d)</span> The method or methods by which the health care consumer can access the patient’s own sensitive health information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(5)(e)">(e)</span> The circumstances under which an HIE must restrict or may disclose legally protected health information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(5)(f)">(f)</span> The method by which a health care consumer can request that a patient’s legally protected health information be disclosed to a specific health care provider.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#B(6)">(6)</span> When an HIE updates its health care consumer educational content, the HIE shall timely make the updated materials available to health care consumers.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C">C.</span> An HIE shall comply with the following requirements to allow a health care consumer to obtain information concerning a patient's PHI that may be available through the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(1)">(1)</span> An HIE shall provide the following information to the health care consumer, upon written notice or request by the health care consumer, describing what PHI is available through the HIE concerning the specified patient:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(1)(a)">(a)</span> The participating organization that disclosed the PHI to the HIE;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(1)(b)">(b)</span> The date the PHI was disclosed to the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(1)(c)">(c)</span> The type of PHI disclosed to the HIE, if known by the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(2)">(2)</span> An HIE shall provide written information, in accordance with this Regulation, to health care consumers concerning the methods available to such health care consumers to access a patient's PHI that is available through the HIE.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(2)(a)">(a)</span> If the patient's PHI is directly available electronically to the health care consumer through the HIE, the HIE shall advise the health care consumer how to obtain the PHI electronically.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(2)(b)">(b)</span> If the patient's PHI is not directly available electronically to the health care consumer through the HIE, the HIE shall, within 7 days from receipt of such health care consumer's written notice or request, provide the health care consumer with the contact information for each participating organization that has disclosed information to the HIE and received information from the HIE concerning the patient, so that the health care consumer may gain access to the patient's health information directly from each participating organization.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(3)">(3)</span> An HIE shall make a good faith effort to facilitate a health care consumer's amendment of the patient's health information available through the HIE by informing the health care consumer how to seek amendment of the information.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(3)(a)">(a)</span> An HIE shall send information regarding the process for amending health information being made available through the HIE within 20 days of receiving notice from a health care consumer of a desire to amend the patient's health information available through the HIE and shall include the contact information of relevant participating organizations that provided the information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(3)(b)">(b)</span> This process shall be in accordance with the requirements specified in Health-General Article, §4-304(b), Annotated Code of Maryland and HIPAA, including 45 CFR §164.526.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(3)(c)">(c)</span> An HIE shall make a good faith effort to notify the participating organization of each authorized user who has accessed, used, or disclosed the health information that has subsequently been amended.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)">(4)</span> Upon receipt of written notice or request, an HIE shall provide each health care consumer with a report detailing any disclosure through the HIE for a time period specified by the health care consumer, of the patient's PHI. In the case of recurring disclosures to the same entity for the same purpose, a summary report may be provided by the HIE. However, if the health care consumer requests the details of the summary report, the HIE shall promptly provide them.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(a)">(a)</span> The time period specified by the health care consumer shall not exceed the data retention period as specified in the HIPAA Privacy Rule, 45 CFR §164.528.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(b)">(b)</span> The report shall specify the following for each instance that the patient's PHI was disclosed during the time frame reflected in the report:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(b)(i)">(i)</span> The name of each authorized user;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(b)(ii)">(ii)</span> The name of the participating organization to which the authorized user is affiliated, if such information is kept by the HIE in the ordinary course of business;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(b)(iii)">(iii)</span> The date and time of the disclosure;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(b)(iv)">(iv)</span> The type of PHI disclosed, if known by the HIE; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(b)(v)">(v)</span> The name of the participating organization that made the protected health information available to the HIE.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(c)">(c)</span> An HIE shall acknowledge a health care consumer's written notice or request for the report within 10 business days of receipt of the request.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(d)">(d)</span> An HIE shall respond to a health care consumer's written notice or request with either the requested report or with a written explanation why such report is unavailable, when it will be available, or where the health care consumer may obtain the requested information, in accordance with 45 CFR §164.528(a)(2)(D)(3). The HIE shall respond within a reasonable time frame, but not later than 30 days of the initial written notice or request by the health care consumer.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(d)(i)">(i)</span> An HIE shall provide up to two copies annually of the report at no cost to the health care consumer, upon written notice or request by the consumer. If the report is available in an electronic format, it shall be provided to the consumer in a generally available electronic format such as PDF, if so requested, at no additional charge.</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#C(4)(d)(ii)">(ii)</span> For any additional report, the HIE may charge a reasonable fee not to exceed the cost to provide the additional report, but no more than the allowable amount in accordance with Health-General Article, §4-304, Annotated Code of Maryland, and 45 CFR §164.524(c)(4).</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D">D.</span> Consent Management Application.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)">(1)</span> The State-designated HIE shall implement a consent management application that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)(a)">(a)</span> Allows a person in interest to opt out of or opt in to having a patient’s electronic health information shared or disclosed by an HIE;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)(b)">(b)</span> Allows a person in interest to view the interested patient’s opt-out status.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)(c)">(c)</span> Informs the person in interest of the types of electronic health information that may be shared or disclosed by the State-designated HIE in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#A(2)(a)" title="">§A(2)(a) of this regulation</a> notwithstanding the choice to opt out;;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)(d)">(d)</span> Enables HIEs to readily identify information as to whether a person in interest has opted out of sharing the patient’s electronic health information; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)(e)">(e)</span> At least includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)(e)(i)">(i)</span> Personal identifiers consisting of the full name, date of birth, mailing address, telephone number, medical record number, and other unique identifiers of the patient and person in interest, if not the patient;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)(e)(ii)">(ii)</span> The person in interest’s communication contact preferences;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)(e)(iii)">(iii)</span> The relationship of the person in interest to the patient; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(1)(e)(iv)">(iv)</span> The date the patient’s consent preferences were last updated.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(2)">(2)</span> Within 12 months of the effective date of this regulation, the State-designated HIE shall make the consent management application it develops available to registered HIEs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(3)">(3)</span> The State-designated HIE shall implement the consent management application with a secure electronic interface that supports standardized interoperability between various recipient HIE systems.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(4)">(4)</span> HIE Connection to the Consent Management Application.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(4)(a)">(a)</span> Exception. Section D(4)(b) of this regulation does not apply to an HIE that solely exchanges electronic health information with other HIEs and does not have any health care providers as a participating organization.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(4)(b)">(b)</span> An HIE shall:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(4)(b)(i)">(i)</span> Establish bi-directional connectivity with the consent management application within 12 months of receiving notification from the State-designated HIE that the application is operational;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(4)(b)(ii)">(ii)</span> Update the HIE's system with the most recent version of the consent management application data at least every 5 business days;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(4)(b)(iii)">(iii)</span> Update the consent management application with any opt-out or opt-in requests it has received from an HIE or directly from a person in interest within 5 business days;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(4)(b)(iv)">(iv)</span> Withhold sharing or disclosure of the electronic health information of a patient to the extent the consent management application indicates that the patient has opted out of having electronic health information shared or disclosed by an HIE, except to the extent permitted by <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#A(2)" title="">§A(2) of this regulation</a>; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(4)(b)(v)">(v)</span> Electronically notify authorized users when a patient has restricted data sharing.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(5)">(5)</span> An HIE shall implement the consent management application in a manner that is consistent with this chapter, its existing policies and procedures regarding use and disclosure of PHI and other personal identifiable information, and its technological capabilities.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(6)">(6)</span> An HIE shall place a link on its website directing a person in interest to the State-designated HIE’s website to globally opt out or opt in to having a patient’s electronic health information shared or disclosed by an HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(7)">(7)</span> An HIE shall continue to accept opt-out and opt-in requests from health care consumers directly.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(8)">(8)</span> The State-designated HIE shall promptly notify the Commission and all HIEs any time the consumer management application is not operational and when services are resumed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(9)">(9)</span> An HIE is not required to comply with <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#D(4)(b)" title="">§D(4)(b) of this regulation</a> when:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(9)(a)">(a)</span> An emergency exists and all requirements under <a class="internal-link " href="/us/md/exec/comar/10.25.18.11" title=".11 Requirements for Accessing, Using, or Disclosing of Data Through an HIE in an Emergency.">Regulation .11 of this chapter</a> have been met; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(9)(b)">(b)</span> The consent management application is not operational.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#D(10)">(10)</span> Section D of this regulation shall be in addition to any restrictions on the disclosure of sensitive health information, consistent with <a class="internal-link " href="/us/md/exec/comar/10.25.18.04" title=".04 Access, Use, or Disclosure of Sensitive Health Information.">Regulation .04 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#E">E.</span> An HIE shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#E(1)">(1)</span> Establish and maintain an online process that allows health care consumers to obtain an electronic report detailing any disclosures of their information through the HIE in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#C(4)(b)" title="">§C(4)(b) of this regulation</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#E(2)">(2)</span> Implement and maintain compliance with the provisions detailed in Regulation .12A(1)(7), B(1)(2), and C(4)(b)(d) of this chapter in implementing <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#E(1)" title="">§E(1) of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#F">F.</span> An HIE shall take affirmative steps to protect a patient's protected health information, including sensitive health information, that is accessible to or through the HIE from a breach or a non-HIPAA violation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#F(1)">(1)</span> An HIE shall have an easily accessible and convenient method by which a person may notify the HIE concerning a potential or an actual breach or a non-HIPAA violation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#F(2)">(2)</span> When an HIE is notified in writing of a potential or an actual breach or a non-HIPAA violation, the HIE shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#F(2)(a)">(a)</span> Acknowledge receipt of the notification within 1 business day;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#F(2)(b)">(b)</span> Begin an investigation concerning the matter upon receipt of the notification in compliance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.07" title=".07 Remedial Actions to Be Taken by an HIE.">Regulation .07 of this chapter</a> and;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#F(2)(c)">(c)</span> In accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.08" title=".08 Notice of Breach and non-HIPAA Violation.">Regulation .08 of this chapter</a>, provide the person filing the notification and each health care consumer whose protected health information was breached with information concerning the determination and resolution of the matter by the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#F(3)">(3)</span> An HIE shall implement robust technical measures consistent with generally accepted industry best practices to assure valid patient identification and minimize patient record mismatches.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#G">G.</span> An HIE shall implement a process to allow a health care consumer to make an educated decision regarding the patient's participation in an HIE, opting out from such participation, or opting to resume participation in the HIE system, in accordance with this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#G(1)">(1)</span> An HIE shall maintain a log that records each patient's participation status over time; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#G(1)(a)">(a)</span> The HIE shall retain the log for the duration required by State or federal law, whichever requires a longer retention; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#G(1)(b)">(b)</span> The HIE shall keep the log in a retrievable storage medium.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#G(2)">(2)</span> An HIE may not disclose a patient's PHI if the health care consumer has submitted a written notice or request to opt out of the HIE in accordance with §(A)(2) of this regulation except as otherwise permitted under applicable law and in accordance with this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#G(3)">(3)</span> An HIE may not disclose information derived from a patient's PHI, including for secondary use, if the health care consumer has submitted a written notice or request to opt-out of the HIE, except as otherwise permitted under applicable law.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#G(4)">(4)</span> An HIE may not unreasonably deny a health care consumer’s expressed preferences.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H">H.</span> The following requirements shall apply to all communications between an HIE and a health care consumer:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(1)">(1)</span> An HIE shall implement a process to allow a health care consumer to communicate with the HIE about the patient's participation status through an appropriate medium of the health care consumer's choice, including the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(1)(a)">(a)</span> By telephone, via a toll-free number;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(1)(b)">(b)</span> By mail, via a standardized form;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(1)(c)">(c)</span> By fax, via a standardized form;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(1)(d)">(d)</span> Online, via a secure website; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(1)(e)">(e)</span> In person at the HIE's offices during business hours.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(2)">(2)</span> A health care consumer’s communication opting out or opting in to an HIE shall be made:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(2)(a)">(a)</span> In writing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(2)(b)">(b)</span> Online; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(2)(c)">(c)</span> By telephone, if the HIE confirms the action with a written communication to the health care consumer in accordance with §H(5)(a) and (b) of this regulation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(3)">(3)</span> An HIE shall take appropriate measures to assure that a health care consumer who communicates with the HIE is authorized to act on behalf of the patient.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(4)">(4)</span> An HIE shall implement the health care consumer's requested action within 5 business days of receipt of the health care consumer's written or online request concerning:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(4)(a)">(a)</span> Opting out of the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(4)(b)">(b)</span> Resuming participation in the HIE after previously opting out.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(5)">(5)</span> An HIE shall provide to each health care consumer the option to receive confirmation of any change in the patient's participation status. If a health care consumer requests such confirmation in writing, the HIE shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(5)(a)">(a)</span> Send the confirmation of participation status change within 3 business days of the effective date of change of such patient's participation status; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(5)(b)">(b)</span> If consistent with all applicable privacy and security law and regulations, including HIPAA and applicable State law and regulations, send the confirmation of status change through one of the following methods as specified by the health care consumer:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(5)(b)(i)">(i)</span> An email sent to the email address specified by the health care consumer;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(5)(b)(ii)">(ii)</span> A letter to an address specified by the health care consumer;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(5)(b)(iii)">(iii)</span> A letter by fax to a fax number specified by the health care consumer;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(5)(b)(iv)">(iv)</span> A letter given to the health care consumer at the HIE during normal business hours; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(5)(b)(v)">(v)</span> A text message sent to the number specified by the health care consumer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(6)">(6)</span> When a health care consumer changes the patient's participation status, the HIE shall provide the following to the health care consumer and, unless the patient is a minor or subject to a power of attorney or otherwise unable to handle his or her own affairs, to the patient:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(6)(a)">(a)</span> Information concerning when the status change will become effective; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#H(6)(b)">(b)</span> Information concerning what information will be excluded from the HIE regarding a health care consumer who opts out.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#I">I.</span> A participating organization shall comply with the following requirements to assure patient and health care consumer rights.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#I(1)">(1)</span> A participating organization shall inform each health care consumer no later than the first medical encounter following enrollment of the organization in an HIE, by written and oral notice, of:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#I(1)(a)">(a)</span> Such organization's participation in an HIE, including in such organization's Notice of Privacy Practices under HIPAA; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#I(1)(b)">(b)</span> Information concerning the health care consumer's right to opt out from participation in the HIE and the process to opt out; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#I(1)(c)">(c)</span> The types of information the participating organization will disclose to the HIE and for what purposes information accessed through the HIE may be used for treatment, payment, health care operations, and secondary use as described in this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.03#I(2)">(2)</span> In addition to applicable HIPAA notification requirements, a participating organization shall notify each health care consumer whose protected health information, including sensitive health information, is breached or is maintained, accessed, used, or disclosed in a manner that constitutes a non-HIPAA violation in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.08" title=".08 Notice of Breach and non-HIPAA Violation.">Regulation .08 of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.04" data-order="|10|25|18|.04|" data-ref-path="10|25|18|.04" class="h__section">.04 Access, Use, or Disclosure of Sensitive Health Information.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A">A.</span> Consistency with Disclosure Requirements Under Federal and State Law.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(1)">(1)</span> A person shall comply with all relevant State and federal laws, including 42 CFR Part 2, and Health-General Article, §4-302.5, Annotated Code of Maryland, concerning the access, use, or disclosure of sensitive health information through an HIE and maintenance of such information by an HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(2)">(2)</span> If federal or State law requires written consent or authorization for access, use, or disclosure of sensitive health information, a person shall obtain consent or authorization consistent with the applicable law prior to the access, use, or disclosure of sensitive health information to and through an HIE to an authorized recipient.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(3)">(3)</span> If federal or State law does not require written consent or authorization for access, use, or disclosure of sensitive health information, a person may not require consent or authorization prior to the access, use, or disclosure of the sensitive health information through an HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(4)">(4)</span> An HIE shall use only point-to-point transmission to allow access, use, or disclosure of the sensitive health information through an HIE, unless the HIE implements:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(4)(a)">(a)</span> Nationally recognized standards that support control by the health care consumer over the electronic exchange of the patient's sensitive health information consistent with the privacy and consent directives made by the health care consumer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(4)(b)">(b)</span> Electronic exchange controls and processes that:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(4)(b)(i)">(i)</span> Support granular patient consent for the electronic transmission of sensitive health information consistent with applicable State and federal laws concerning the access, use, or disclosure of sensitive health information, including applicable standards and technical requirements in accordance with Part 2; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(4)(b)(ii)">(ii)</span> Assure that the health care consumer's granular consent controls remain associated with the sensitive health information and are adhered to as the information is transmitted through, maintained, or disclosed by the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(4)(c)">(c)</span> Health care consumer educational content:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(4)(c)(i)">(i)</span> That is developed and established in coordination with the Commission and stakeholders;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(4)(c)(ii)">(ii)</span> That is kept current; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(4)(c)(iii)">(iii)</span> The receipt of which shall be acknowledged by the health care consumer as part of the granular consent process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(5)">(5)</span> In the case of the improper access, use, maintenance, or disclosure of sensitive health information, including an inadvertent release through an HIE, a participating organization shall take the following actions in addition to any other requirement imposed under federal or State law:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(5)(a)">(a)</span> Take all steps necessary to immediately stop any further improper access, use, disclosure, or release of the patient's sensitive health information through the HIE and the improper maintenance of such information by the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#A(5)(b)">(b)</span> In accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.08" title=".08 Notice of Breach and non-HIPAA Violation.">Regulation .08 of this chapter</a>, notify each health care consumer whose sensitive health information has been accessed, used, maintained, or disclosed in violation of applicable State or federal laws, including a non-HIPAA violation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#B">B.</span> Procedure for Disclosing or Re-disclosing of Part 2 Health Information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#B(1)">(1)</span> An HIE shall be in compliance with Part 2</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#B(2)">(2)</span> A participating organization that is a Part 2 program, as that term is defined by Part 2, shall identify itself as such and clearly indicate with all of its patient records any limits on use or disclosure required by Part 2.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#B(3)">(3)</span> An HIE or participating organization that receives Part 2 information may not re-disclose such information without appropriate patient consent or authorization except as permitted by applicable federal and State laws and regulations.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C">C.</span> Procedures for Disclosing or Re-Disclosing Legally Protected Health Information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(1)">(1)</span> An HIE shall be in compliance with Health-General Article, §4-302.5, Annotated Code of Maryland, and <a class="internal-link no-wrap" href="/us/md/exec/comar/10.11.08" title="Chapter 08 Abortion Care Disclosure">COMAR 10.11.08</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)">(2)</span> By January 8, 2024, an HIE shall submit to the Commission:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)(a)">(a)</span> An affirmation that it:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)(a)(i)">(i)</span> Possesses the technological capability to filter and restrict from disclosure legally protected health information to the extent required by law;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)(a)(ii)">(ii)</span> Is parsing restricted codes and conveying all other information in the health record that is not prohibited by law to exchange; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)(a)(iii)">(iii)</span> Possesses the technological capacity to allow a consumer to request and consent to the exchange of legally protected health information to a specific treating provider; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)(b)">(b)</span> An implementation plan that includes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)(b)(i)">(i)</span> An affirmation that, despite its best efforts, the HIE lacks the technological capability to fully comply with <a class="internal-link " href="/us/md/exec/comar/10.25.18.04#C(1)" title="">§C(1) of this regulation</a> as of January 8, 2024, including a detailed explanation of the HIE’s limitations;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)(b)(ii)">(ii)</span> A detailed description of the steps the HIE is taking to ensure compliance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.04#C(1)" title="">§C(1) of this regulation</a> by June 1, 2024;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)(b)(iii)">(iii)</span> A timeline to implement the requirements of Health-General Article §4-302.5, Annotated Code of Maryland, by June 1, 2024; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(2)(b)(iv)">(iv)</span> A description of the extent legally protected health information and other health information will be restricted through the HIE during the implementation of its plan.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(3)">(3)</span> If an HIE submits an implementation plan in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.04#C(2)(b)" title="">§C(2)(b) of this regulation</a>, the HIE shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(3)(a)">(a)</span> Notify all participating organizations by January 8, 2024, that the HIE is unable to comply with <a class="internal-link " href="/us/md/exec/comar/10.25.18.04#C(1)" title="">§C(1) of this regulation</a> with a written notice that describes the extent legally protected health information and other health information will be restricted through the HIE during the implementation of its plan;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(3)(b)">(b)</span> Provide a status report to the Commission by April 1, 2024, detailing the progress the HIE has made under its implementation plan; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(3)(c)">(c)</span> Submit validation to the Commission by June 1, 2024, that it possesses the technological capability to filter and restrict from disclosure legally protected health information to the extent required by law.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.04#C(4)">(4)</span> The Commission shall consider an HIE’s implementation plan and reported progress when assessing penalties for a violation of this section.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.05" data-order="|10|25|18|.05|" data-ref-path="10|25|18|.05" class="h__section">.05 Requirements for Accessing, Using, or Disclosing Health Information Through an HIE.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#A">A.</span> As a requirement of participation in an HIE, the HIE shall require each participating organization to enter into a binding participation agreement that:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#A(1)">(1)</span> Requires the participating organization and each authorized user to comply with this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#A(2)">(2)</span> Requires the participating organization and each authorized user to comply with all applicable federal and State privacy and security laws; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#A(3)">(3)</span> Includes a business associate agreement:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#A(3)(a)">(a)</span> In compliance with 45 CFR §164.504; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#A(3)(b)">(b)</span> If the participating organization will maintain Part 2 information, the business associate agreement shall comply with the additional requirements that apply to a qualified service organization under 42 C.F.R. §2.11.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#A(4)">(4)</span> Permits PHI disclosed through the HIE to the authorized user of a participating organization to be incorporated into the patient’s medical record kept by such participating organization, and requires compliance with all applicable federal and State laws.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#B">B.</span> An HIE shall only disclose PHI through an HIE for a primary use consistent with the following:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#B(1)">(1)</span> The disclosure shall be only to an authorized user for the specific purpose for which that authorized user is given access to the PHI; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#B(2)">(2)</span> All disclosures shall be in full compliance with these regulations.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#C">C.</span> The Commission may suspend the registration, in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.09" title=".09 Registration and Enforcement.">Regulation .09 of this chapter</a>, of a registered HIE that inappropriately discloses to any person any PHI, or health information derived from PHI, that is available through the HIE’s infrastructure, except as consistent with or otherwise permitted by this chapter and applicable federal or State law.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D">D.</span> To assure that only an authorized user accesses, uses, or discloses PHI through or from an HIE, an HIE shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(1)">(1)</span> Develop and maintain an HIE access matrix that includes the defined HIE access levels available to each authorized user.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(1)(a)">(a)</span> The HIE access matrix shall be used for the following purposes:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(1)(a)(i)">(i)</span> To assign an HIE access level to each staff member of the HIE or its contractor that allows only the minimum necessary access to PHI to perform that staff member’s authorized purpose; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(1)(a)(ii)">(ii)</span> To assist each participating organization and its system administrator in assigning the appropriate HIE access level to each authorized user of that participating organization.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(1)(b)">(b)</span> The HIE shall review its HIE access matrix annually and revise it as necessary to reflect relevant changes in technology, standards, or law; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(1)(c)">(c)</span> The HIE shall have the necessary technological capabilities in its core infrastructure to limit an authorized user’s access to the HIE according to the then currently assigned access level of its access matrix.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(2)">(2)</span> Provide technical assistance and guidance to the system administrator of each participating organization in assigning the appropriate HIE access level to each of its authorized users;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(3)">(3)</span> Comply, at a minimum, with the most recent Level 2 requirements set by the National Institute of Standards and Technology (NIST), as set forth in April 2006 in Special Publication 800-63 (Version 1.0.2): Electronic Authentication Guideline for both Registrations and for Registration Record Retention; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(4)">(4)</span> Adopt and implement an authentication process that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(4)(a)">(a)</span> Requires the authentication of an authorized user at each “log in” prior to allowing that individual access to the HIE;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(4)(b)">(b)</span> Requires a single factor authentication with two characteristics that include a user name and a password, along with an additional security precaution, which may include a security question or a device registration.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(4)(c)">(c)</span> Ensures that the data stored in the HIE that is used to authenticate an authorized user is encrypted to the level set by industry best practices; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(5)">(5)</span> Accept as valid a third party system’s authentication of an authorized user accessing the HIE through that third party system, as long as such access and third party system:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(5)(a)">(a)</span> Permits the HIE to audit and monitor the user’s HIE activities; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(5)(b)">(b)</span> The HIE has received written assurances from the third party system that it is compliant with these regulations and all applicable federal and State privacy and security regulations.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#D(6)">(6)</span> If an HIE learns or has reason to believe that the third party system is not compliant, then it shall immediately cease acceptance of such third party system’s authentication of authorized users until the third party system demonstrates compliance to the reasonable satisfaction of the HIE.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E">E.</span> To assure that only an authorized user accesses, uses, or discloses PHI through or from an HIE, a participating organization shall comply with each of the following.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(1)">(1)</span> A participating organization shall designate a system administrator who is capable of carrying out the requirements set forth in <a class="internal-link " href="/us/md/exec/comar/10.25.18.05#F" title="">§F of this regulation</a> on behalf of the participating organization prior to exchanging any PHI through the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(2)">(2)</span> A participating organization shall promptly inform its system administrator of any circumstances that require any of the actions described under <a class="internal-link " href="/us/md/exec/comar/10.25.18.05#F" title="">§F of this regulation</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(3)">(3)</span> A participating organization shall ensure that any third party system it uses appropriately authenticates an authorized user prior to allowing that individual access to the HIE through the third party system.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(3)(a)">(a)</span> The third party system shall authenticate an authorized user at each “log in.”</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(3)(b)">(b)</span> The third party system shall ensure that the data stored in the system which is used to authenticate an authorized user is encrypted to the level set by industry best practices.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(3)(c)">(c)</span> A participating organization shall adopt and implement a protocol to be followed by a third party system that requires a user name, a password, and an additional security precaution which may include a security question or a device registration.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(4)">(4)</span> A participating organization shall inform the HIE concerning the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(4)(a)">(a)</span> The designation of the system administrator, or any change in such designation, within 5 business days of any such designation or change;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(4)(b)">(b)</span> A breach or non-HIPAA violation by a person who had or has access to the HIE through the participating organization; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#E(4)(c)">(c)</span> An act or event that it has a reasonable basis to believe is or may be a significant violation of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F">F.</span> The system administrator of a participating organization shall carry out each of the following measures on behalf of the participating organization.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F(1)">(1)</span> The system administrator shall identify each authorized user within the participating organization and shall note the individual’s assigned unique user name in accordance with the most recent applicable standards issued by NIST, or other comparable standards generally adopted by the health care and HIE industry.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F(2)">(2)</span> The system administrator and HIE shall coordinate with the Commission to determine a methodology for assigning each authorized user with a unique user name and password and to assure that all HIEs use a commonly accepted protocol to avoid the possibility of duplicate user names and passwords.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F(3)">(3)</span> The system administrator, in coordination with the HIE, shall assign to each authorized user an access level that appropriately corresponds to that individual’s role within the participating organization and the permitted access to PHI available through the HIE on behalf of the participating organization.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F(4)">(4)</span> The system administrator shall modify in a timely manner an authorized user’s access level as appropriate to reflect any change in that individual’s role within the participating organization; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F(5)">(5)</span> The system administrator shall immediately terminate access through an HIE in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.07" title=".07 Remedial Actions to Be Taken by an HIE.">Regulation .07 of this chapter</a> for any authorized user:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F(5)(a)">(a)</span> Who is suspended by the participating organization;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F(5)(b)">(b)</span> Who is no longer associated with the participating organization; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F(5)(c)">(c)</span> Who no longer requires access to the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.05#F(6)">(6)</span> The system administrator shall attest to the HIE regarding the appropriateness of a staff member to be an authorized user and that the HIE access level assigned to that staff member corresponds to the authorized user’s role within the participating organization.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.06" data-order="|10|25|18|.06|" data-ref-path="10|25|18|.06" class="h__section">.06 Auditing Requirements.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A">A.</span> In order to ensure that only an authorized user who is appropriately authenticated is granted access to HIE information, an HIE shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(1)">(1)</span> Develop and implement protocols, methodologies, and a monitoring approach designed to discover any unusual finding, which may be identified within an audit of the user access logs, including conducting ongoing electronic monitoring of user access logs and investigate any unusual findings in accordance with this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(2)">(2)</span> Conduct each audit under this regulation in accordance with best practices using industry accepted standards and methodologies;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(3)">(3)</span> Conduct random audits of the user access logs to identify any unusual finding; and, if the HIE has been notified about an unusual finding or has reason to believe that inappropriate access has occurred, conduct random audits at least every other week until the unusual finding or inappropriate access has been mitigated;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(4)">(4)</span> At least quarterly, conduct random audits of security measures and any other forms of data security in place to determine if they are still sufficient and compliant with applicable standards;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(5)">(5)</span> Investigate each unusual finding identified in the access log audit to determine if there has been a violation of <a class="internal-link " href="/us/md/exec/comar/10.25.18.05" title=".05 Requirements for Accessing, Using, or Disclosing Health Information Through an HIE.">Regulation .05 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(6)">(6)</span> Resolve an unusual finding by:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(6)(a)">(a)</span> Taking actions necessary to correct each identified technical control deficiency; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(6)(b)">(b)</span> Taking remedial action under <a class="internal-link " href="/us/md/exec/comar/10.25.18.07" title=".07 Remedial Actions to Be Taken by an HIE.">Regulation .07 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(7)">(7)</span> Report any unusual finding to each participating organization involved in the unusual finding, as follows:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(7)(a)">(a)</span> If the unusual finding involves fewer than 10 patients, within 5 business days after the unusual finding is discovered;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(7)(b)">(b)</span> If the unusual finding involves between 10 and 50 patients, within 2 business days after the unusual finding is discovered; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(7)(c)">(c)</span> If the unusual finding involves more than 50 patients, within 1 business day after the unusual finding is discovered; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(8)">(8)</span> Maintain an audit trail of user access logs in a retrievable storage medium, as follows:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(8)(a)">(a)</span> The HIE shall perform periodic testing to ensure that the storage medium being used will allow the data to be recovered.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(8)(b)">(b)</span> The HIE shall perform periodic testing and implement upgrades and updates to ensure that the storage medium is secure and has not been improperly accessed.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#A(8)(c)">(c)</span> The data shall be kept for the longest duration of time identified in applicable State and federal requirements.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#B">B.</span> When an HIE has identified a potential breach or non-HIPAA violation, the HIE shall conduct an unscheduled audit within 30 days that:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#B(1)">(1)</span> Gathers relevant information to determine if there is a violation;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#B(2)">(2)</span> Reflects the size and scope of the potential violation; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#B(3)">(3)</span> Complies with <a class="internal-link " href="/us/md/exec/comar/10.25.18.08" title=".08 Notice of Breach and non-HIPAA Violation.">Regulation .08 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C">C.</span> An HIE shall at least annually enlist a qualified independent auditing firm to audit its privacy, security, and legal compliance in accordance with the following provisions:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(1)">(1)</span> The audit shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(1)(a)">(a)</span> Assess potential risks to protect the confidentiality, integrity, and security of PHI;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(1)(b)">(b)</span> Assess operational compliance with State and federal law, including the requirements of this chapter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(1)(c)">(c)</span> Be designed to determine the adequacy of business and technology-related controls, policies, and procedures and other safeguards employed by third-party service organizations based on industry standards and best practices; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(1)(d)">(d)</span> Include an assessment of cybersecurity posture and compliance with this chapter, applicable provisions in HIPAA and HITECH, and recognized security practices by way of accreditation or certification from a nationally recognized entity.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(2)">(2)</span> An HIE shall develop auditing policies and procedures for the independent auditor to conduct such an audit, which shall include, at a minimum:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(2)(a)">(a)</span> The scope of the audit;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(2)(b)">(b)</span> A description of all third-party organizations and processes to review and assess related privacy and security controls and audit reports;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(2)(c)">(c)</span> Interviews with relevant staff, including those from third-party service organizations, as appropriate;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(2)(d)">(d)</span> Names and contact information of all persons responsible for reviewing and maintaining privacy and security to include the implementation of corrective actions to address apparent gaps; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(2)(e)">(e)</span> Time frames for completing audits and related activities.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(3)">(3)</span> An HIE shall provide the audit findings to the Commission in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.09" title=".09 Registration and Enforcement.">Regulation .09 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#C(4)">(4)</span> If an audit detects unusual findings, an HIE shall investigate and resolve the matter in accordance with this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#D">D.</span> Upon the request of the Commission and consistent with the specifications in such request, an HIE shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#D(1)">(1)</span> Provide a summary of the results of any audit that is required by this chapter, and any corrective action plans identified by the audit, to the Commission; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#D(2)">(2)</span> Conduct an additional unscheduled audit within 180 days of the request and provide the results of such an audit to the Commission within the time frame specified by the Commission.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#E">E.</span> If an HIE’s audit reveals information that demonstrates a pattern of inappropriate access, use, maintenance, or disclosure of information that constitutes a breach or non-HIPAA violation, or if the health information of more than ten patients was improperly used, accessed, maintained, or disclosed during the 12 months prior to the audit, then:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#E(1)">(1)</span> The HIE shall use the findings from the audit to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#E(1)(a)">(a)</span> Educate and train all impacted persons, which may include its workforce, participating organizations, and authorized users on proper access, use, and disclosure of information through or from the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#E(1)(b)">(b)</span> Evaluate and implement new control measures, including policies, procedures, or technology, to ensure proper use and access of the HIE; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#E(2)">(2)</span> The HIE shall take the appropriate measures specified in <a class="internal-link " href="/us/md/exec/comar/10.25.18.07" title=".07 Remedial Actions to Be Taken by an HIE.">Regulation .07 of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#F">F.</span> If an HIE’s audit reveals information that demonstrates a pattern of noncompliance with State and federal law, then:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#F(1)">(1)</span> The HIE shall use the findings from the audit to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#F(1)(a)">(a)</span> Educate and train all impacted persons, which may include its workforce, participating organizations, and authorized users on proper access, use, and disclosure of information through or from the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#F(1)(b)">(b)</span> Evaluate and implement new control measures, including policies, procedures, or technology, to ensure compliance; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#F(2)">(2)</span> The HIE shall take the appropriate measures specified in the Regulation. 07 of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G">G.</span> An HIE and its participating organizations shall adopt an access and auditing plan that requires the HIE and each participating organization, as applicable, to conduct a random audit of the HIE access logs on a monthly basis.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(1)">(1)</span> The random audit included in the plan shall be assigned to the HIE or the participating organizations according to their respective system's technological capabilities.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(2)">(2)</span> The access and auditing plan shall include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(2)(a)">(a)</span> The manner used to identify a non-HIPAA violation of this chapter or a breach;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(2)(b)">(b)</span> The method to be used to report a non-HIPAA violation of this chapter or a breach;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(2)(c)">(c)</span> The reasonable steps that will be taken to promptly mitigate a non-HIPAA violation of this chapter or a breach; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(2)(d)">(d)</span> A review of access logs to ensure that only an authorized user who is appropriately authenticated is granted access to HIE information through a participating organization's third party system.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(3)">(3)</span> If a participating organization does not conduct its own audit, it shall review the HIE access logs relating to the participating organization within 10 days of receipt from the HIE. An HIE shall send HIE access logs to each participating organization no less than quarterly.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(3)(a)">(a)</span> The purpose of the review is to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(3)(a)(i)">(i)</span> Detect patterns of inappropriate access, use, maintenance, or disclosure; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(3)(a)(ii)">(ii)</span> Compare the PHI accessed by the authorized user with the health care provided to assure that the authorized user's use of the HIE is appropriate.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(3)(b)">(b)</span> In order to conduct the quarterly review, the HIE shall provide a participating organization with audit record information concerning the participating organization's authorized users access of the HIE that shall include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(3)(b)(i)">(i)</span> The name and access level of each user;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(3)(b)(ii)">(ii)</span> The name of the patient whose PHI was accessed;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(3)(b)(iii)">(iii)</span> The date and time of access; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.06#G(3)(b)(iv)">(iv)</span> The type of PHI that was accessed.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.07" data-order="|10|25|18|.07|" data-ref-path="10|25|18|.07" class="h__section">.07 Remedial Actions to Be Taken by an HIE.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#A">A.</span> An HIE shall immediately suspend a person's access to the HIE when it is necessary to avoid serious harm to the privacy or security of health information accessed, used, or disclosed through or from the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#A(1)">(1)</span> An HIE may, in its sole discretion, suspend a person's access to the HIE pursuant to this section before an investigation under <a class="internal-link " href="/us/md/exec/comar/10.25.18.07#B" title="">Regulation .07B of this chapter</a> is completed. In addition, if the HIE determines that serious harm to the privacy or security of health information or an ongoing risk of improper use, access, maintenance, or disclosure of PHI may occur prior to conclusion of an investigation, it shall suspend a person’s access to the HIE pursuant to this section before an investigation is complete.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#A(2)">(2)</span> Such suspension shall continue until the underlying threat to the privacy or security of health information is contained.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#B">B.</span> An HIE shall conduct an investigation if there is reason to believe that a breach or non-HIPAA violation has occurred.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#B(1)">(1)</span> The HIE shall begin the investigation upon learning of the allegations giving rise to a potential breach or violation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#B(2)">(2)</span> The HIE shall conduct the investigation in a thorough, timely, professional manner and take all necessary actions to gather information concerning the potential breach or violation that reflects the size and scope of such potential breach or violation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#B(3)">(3)</span> If appropriate, an investigation shall include an audit under <a class="internal-link " href="/us/md/exec/comar/10.25.18.06" title=".06 Auditing Requirements.">Regulation .06 of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#B(4)">(4)</span> Upon the completion of an investigation, which shall not exceed 14 business days, an HIE shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#B(4)(a)">(a)</span> Make a written finding describing the results of an investigation and provide a copy to the Commission; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#B(4)(b)">(b)</span> Maintain records of each investigation (audits, complaints, breaches, non-HIPAA violations) for at least 5 years from the date of completion of such investigation or 5 years from the date a minor patient becomes an adult, whichever is longer.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C">C.</span> If an HIE has a reasonable belief that a breach or non-HIPAA violation has occurred, either as a result of an investigation or otherwise, the HIE shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(1)">(1)</span> For a breach, follow <a class="internal-link " href="/us/md/exec/comar/10.25.18.08" title=".08 Notice of Breach and non-HIPAA Violation.">Regulation .08 of this chapter</a> and federal breach notification requirements and timelines;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(2)">(2)</span> For non-HIPAA violations, submit a corrective action plan to the Commission within 10 business days of conclusion of its investigation, which shall include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(2)(a)">(a)</span> Any remedial action necessary to address the breach or violation as soon as practicable;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(2)(b)">(b)</span> Any steps necessary to correct the underlying problem, such as a change in processes or procedures, new technology, and training; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(2)(c)">(c)</span> An appropriate and reasonable time frame for implementing the remedial action;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(3)">(3)</span> Within a reasonable time frame, but in no event more than 10 business days following the investigation, provide the following to the Commission, and to the participating organizations:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(3)(a)">(a)</span> A copy of the findings of the investigation, excluding any PHI or sensitive health information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(3)(b)">(b)</span> Each remedial action to be taken by each person and the associated time frame of the remedial action;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(3)(c)">(c)</span> Any action necessary to mitigate the harm that may be caused by the breach or the non-HIPAA violation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(3)(d)">(d)</span> The identity of the person that is responsible for carrying out each action to mitigate harm; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(3)(e)">(e)</span> Any future action that the HIE may take, including suspension of access or progressive discipline, if a person does not comply with the remedial action;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(4)">(4)</span> Immediately suspend access of a person when one of the following occurs:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(4)(a)">(a)</span> Available information demonstrates a significant breach by the person;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(4)(b)">(b)</span> Available information demonstrates a significant non-HIPAA violation by the person;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(4)(c)">(c)</span> Available information demonstrates a violation of State or federal law relevant to privacy or security by the person;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(4)(d)">(d)</span> The person has sold health information accessed through the HIE in violation of these regulations;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(4)(e)">(e)</span> The person has failed to carry out the remedial actions identified by the HIE; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(4)(f)">(f)</span> The Commission issues a request for suspension of the person as provided in <a class="internal-link " href="/us/md/exec/comar/10.25.18.09" title=".09 Registration and Enforcement.">Regulation .09 of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#C(5)">(5)</span> Notify the health care consumer pursuant to <a class="internal-link " href="/us/md/exec/comar/10.25.18.08" title=".08 Notice of Breach and non-HIPAA Violation.">Regulation .08 of this chapter</a>, if such notification is required under applicable law, including HIPAA, or if so directed by the Commission.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#D">D.</span> After verifying that each remedial action is complete, an HIE may reinstate a person's authorization to access information through the HIE provided that:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#D(1)">(1)</span> The Commission has not revoked the person's access to the HIE as provided in <a class="internal-link " href="/us/md/exec/comar/10.25.18.09" title=".09 Registration and Enforcement.">Regulation .09 of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#D(2)">(2)</span> The HIE modifies the person's access as needed to ensure compliance with this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#E">E.</span> A person may file a written notice or request with the Commission that the Commission review an HIEs action under <a class="internal-link " href="/us/md/exec/comar/10.25.18.07" title=".07 Remedial Actions to Be Taken by an HIE.">Regulation .07 of this chapter</a> when the person has reason to believe that the HIE has acted inappropriately.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#E(1)">(1)</span> A request for review shall be filed within 30 days after the person knew or had reason to know of the HIEs action in question;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#E(2)">(2)</span> The request for review shall set forth each reason why the person believes that the HIE's action is inappropriate.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#E(3)">(3)</span> The Commission may determine that no investigation is necessary or may take action under Regulation .09C.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#F">F.</span> An HIE shall provide notice of each suspension and each reinstatement of a person's authorization to access information through an HIE in the following manner:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#F(1)">(1)</span> The HIE shall send an electronic notice to the person who is the subject of the action within 24 hours of the suspension or the reinstatement and to the Commission on a monthly basis.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#F(2)">(2)</span> The notice shall include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#F(2)(a)">(a)</span> The name of the person who is the subject of the action;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#F(2)(b)">(b)</span> The name of any affected participating organization;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#F(2)(c)">(c)</span> The basis for the suspension or reinstatement; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#F(2)(d)">(d)</span> The effective date of the suspension or reinstatement.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#F(3)">(3)</span> The notice shall not include PHI.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.07#F(4)">(4)</span> The notice shall not be considered confidential.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.08" data-order="|10|25|18|.08|" data-ref-path="10|25|18|.08" class="h__section">.08 Notice of Breach and non-HIPAA Violation.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#A">A.</span> Notification of a breach shall be required consistent with notification requirements of applicable federal and State laws, including HIPAA and the HITECH Act.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#B">B.</span> When federal or State law does not require an HIE or other entity to provide notification to a participating organization or to an effected health care consumer, or when Part 2 does not mandate other notification requirements, the HIE shall provide notification of breach and, if applicable, non-HIPAA violations pursuant to this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#B(1)">(1)</span> If the investigation under <a class="internal-link " href="/us/md/exec/comar/10.25.18.07" title=".07 Remedial Actions to Be Taken by an HIE.">Regulation .07 of this chapter</a> concluded that there was a breach or non-HIPAA violation, in addition to applicable HIPAA notification requirements, the HIE shall notify:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#B(1)(a)">(a)</span> The person who notified the HIE of the potential breach or non-HIPAA violation, if applicable, and to the extent permitted by HIPAA and other federal and State privacy laws;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#B(1)(b)">(b)</span> Any participating organization that has provided health information regarding the health care consumer involved; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#B(1)(c)">(c)</span> Each patient or person in interest acting on behalf of each patient whose PHI or sensitive health information was inappropriately accessed or disclosed due to a breach or non-HIPAA violation.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#B(2)">(2)</span> In addition to other requirements specified in this section, the HIE shall include in its notification, the contact information for the HIE, including the address and toll-free telephone number where the health care consumer can learn more information.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C">C.</span> Notification to a Health Care Consumer.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(1)">(1)</span> If the entity providing the notification under this Regulation has knowledge that another person is acting as the health care consumer for the patient, the entity shall provide the notification to that person instead of the patient.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(2)">(2)</span> A notification to the health care consumer required under this Regulation shall be:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(2)(a)">(a)</span> In writing by first-class mail to the health care consumer, at the last known address of the health care consumer, if no prior election as to notice has been made; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(2)(b)">(b)</span> As specified as a preference by the health care consumer under <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#H" title="">Regulation .03H of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(3)">(3)</span> If there is insufficient or out-of-date contact information that precludes notice consistent with this chapter, a substitute form of notice shall be provided. A substitute form of notice may include publishing the notice on the home page of the entity's website to the extent permitted by HIPAA and other federal and State privacy laws.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(4)">(4)</span> When notice about a breach or non-HIPAA violation is required pursuant to this chapter, a participating organization or an HIE, as required, shall notify a health care consumer in writing within a reasonable time frame, but not later than 60 days from the discovery of the breach or from the date that the HIE should have reasonably discovered the breach.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(5)">(5)</span> The written notification shall include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(5)(a)">(a)</span> A description of the breach or non-HIPAA violation that occurred and the remedial actions taken by the participating organization, provided that the notification shall not contain any sensitive health information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(5)(b)">(b)</span> Information about the patient's right to notify credit reporting agencies of the potential for identity theft or medical identity theft;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(5)(c)">(c)</span> Contact information for the HIE, including the address and toll-free telephone number where the health care consumer can learn more information;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(5)(d)">(d)</span> Contact information for at least one credit reporting agency;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(5)(e)">(e)</span> Information concerning the patient's right to opt out of the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(5)(f)">(f)</span> The toll-free numbers, addresses, and websites for:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(5)(f)(i)">(i)</span> The Office of the Attorney General, Consumer Protection Division; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(5)(f)(ii)">(ii)</span> The U.S. Department of Health and Human Services, Office of Civil Rights.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#C(6)">(6)</span> If the entity providing the notification keeps a medical record on the patient, the notification shall be placed within the patient's medical record.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#D">D.</span> Notification to Appropriate Authorities.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#D(1)">(1)</span> Each participating organization and each HIE shall report all violations of federal or State privacy or security law to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#D(1)(a)">(a)</span> Those federal or State authorities to which reporting such violation is required by applicable law, whether or not such laws are specifically set forth in this chapter; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#D(1)(b)">(b)</span> Shall promptly send a copy of such report to the Commission.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.08#D(2)">(2)</span> If the Commission is notified of a breach under this regulation, it shall forward such notification to the Office of the Attorney General, Consumer Protection Division, within 30 days after receipt of the notification.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.09" data-order="|10|25|18|.09|" data-ref-path="10|25|18|.09" class="h__section">.09 Registration and Enforcement.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A">A.</span> To operate an HIE in the State, a person shall be recognized by the Commission as having met requirements for registration.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(1)">(1)</span> A person shall complete an application for registration in a form and manner specified by the Commission that shall include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(1)(a)">(a)</span> The HIE's definition of what constitutes an unusual finding within <a class="internal-link " href="/us/md/exec/comar/10.25.18.06" title=".06 Auditing Requirements.">Regulation .06 of this chapter</a>;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(1)(b)">(b)</span> The HIE's current audited financial statement that demonstrates the financial viability of the HIE;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(1)(c)">(c)</span> The identity of the HIE's registered resident agent who shall accept service in Maryland on behalf of the HIE;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(1)(d)">(d)</span> Documentation showing its technical capabilities, which may include accreditation or candidacy status by a nationally recognized accrediting body; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(1)(e)">(e)</span> Provisions for reasonable notice to participating organizations and the Commission if the HIE ceases to operate in Maryland; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(1)(f)">(f)</span> Other information as required by the Commission.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)">(2)</span> Financial Integrity.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)(a)">(a)</span> Following review of the financial statement provided by the HIE under <a class="internal-link " href="/us/md/exec/comar/10.25.18.09#A(1)(b)" title="">§A(1)(b) of this regulation</a>, the Commission may require a bond, letter of guarantee, or other financial instrument from the HIE, its parent company, or other responsible person.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)(b)">(b)</span> The amount of a bond, letter of guarantee, or other financial instrument required under this regulation shall be established by the Commission and be based on an HIE's financial statement.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)(c)">(c)</span> If a bond is required under <a class="internal-link " href="/us/md/exec/comar/10.25.18.09#A(2)(a)" title="">§A(2)(a) of this regulation</a>, it shall at a minimum:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)(c)(i)">(i)</span> Identify the Commission as the sole beneficiary;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)(c)(ii)">(ii)</span> Be continuous and subject to cancellation only after 60 days' notice to the Commission;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)(c)(iii)">(iii)</span> Contain the following language or similar language acceptable to the Commission: "Payment under this bond shall be due in the event the Commission determines that the HIE is financially insolvent or unable to meet its obligations as a registered HIE in Maryland"; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)(c)(iv)">(iv)</span> Permit the Commission to direct that the proceeds of the bond be paid or disbursed as necessary to maintain or repair the privacy and security of PHI that was or is available through the HIE.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)(d)">(d)</span> If a bond is required under <a class="internal-link " href="/us/md/exec/comar/10.25.18.09#A(2)(a)" title="">§A(2)(a) of this regulation</a>, it shall be obtained from a company licensed in the State to write surety types of insurance.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(2)(e)">(e)</span> If a letter of guarantee or other financial instrument is required under <a class="internal-link " href="/us/md/exec/comar/10.25.18.09#A(2)(a)" title="">§A(2)(a) of this regulation</a>, the guarantor shall submit a current balance sheet and income statement to the Commission.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(3)">(3)</span> Within 45 days after receipt of complete information from an applicant seeking to register as an HIE in the State, the Commission shall take one of the following actions:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(3)(a)">(a)</span> Recognize the HIE as registered in the State; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#A(3)(b)">(b)</span> Deny the registration for reasons enumerated to the applicant.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#B">B.</span> The Commission shall annually renew the registration of an HIE registered in the State that demonstrates its continued compliance with this chapter and provides the following information in a form and manner specified by the Commission, within 120 days of the close of its fiscal year:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#B(1)">(1)</span> Updated information that reflects each change regarding the items in <a class="internal-link " href="/us/md/exec/comar/10.25.18.09#A(1)" title="">§A(1) of this regulation</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#B(2)">(2)</span> Results of an audit performed in compliance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.06" title=".06 Auditing Requirements.">Regulation .06 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#B(3)">(3)</span> As deemed appropriate by the Commission, additional requirements set forth in <a class="internal-link " href="/us/md/exec/comar/10.25.18.09#A(2)" title="">§A(2) of this regulation</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#B(4)">(4)</span> Other information as requested by the Commission.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C">C.</span> The Commission may take an enforcement action against a person when there is reasonable basis to believe that the person has violated a provision of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(1)">(1)</span> The Commission may conduct any investigation into a potential violation.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(1)(a)">(a)</span> A person shall cooperate in an investigation conducted by Commission staff into a potential violation.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(1)(b)">(b)</span> A person shall provide information sought by Commission staff within 10 business days of its request for such information, unless an extension of time is sought for good cause shown and granted by the Commission.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)">(2)</span> After an investigation under <a class="internal-link " href="/us/md/exec/comar/10.25.18.09#C(1)" title="">§C(1) of this regulation</a>, the Commission staff may issue a notice of proposed action that includes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(a)">(a)</span> The details regarding each violation or potential violation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(b)">(b)</span> A request for a person to submit a corrective action plan in order to achieve compliance with this chapter, which may include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(b)(i)">(i)</span> An action aimed at correcting the underlying issue; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(b)(ii)">(ii)</span> Any other action that is appropriate under the circumstances.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(c)">(c)</span> A recommended resolution of the potential violation, which may include:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(c)(i)">(i)</span> Non-public reprimand;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(c)(ii)">(ii)</span> Public reprimand; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(c)(iii)">(iii)</span> Limitations on HIE registration or a person's access to information through an HIE;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(c)(iv)">(iv)</span> Suspension of HIE registration or a person’s access to information through an HIE;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(c)(v)">(v)</span> Revocation of HIE registration or a person’s access to information through an HIE;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(c)(vi)">(vi)</span> Financial penalties in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.09#C(3)" title="">§C(3) of this regulation</a>; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(2)(c)(vii)">(vii)</span> Referral to another State or federal agency for civil or criminal enforcement.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(3)">(3)</span> Civil and Criminal Penalties.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(3)(a)">(a)</span> Civil Penalties. A person who knowingly fails to comply with this chapter shall be subject to a civil penalty imposed by the Commission not exceeding $10,000 per day based on:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(3)(a)(i)">(i)</span> The extent of actual or potential public harm caused by the violation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(3)(a)(ii)">(ii)</span> The cost of the investigation; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(3)(a)(iii)">(iii)</span> The person’s prior record of compliance.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(3)(b)">(b)</span> Criminal Penalties. Beginning June 1, 2024, a person who knowingly violates Health-General Article, §4-302.5, Annotated Code of Maryland, shall be guilty of a misdemeanor and on conviction is subject to a fine not to exceed $10,000 per day based on:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(3)(b)(i)">(i)</span> The extent of actual or potential public harm caused by the violation;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(3)(b)(ii)">(ii)</span> The cost of the investigation; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(3)(b)(iii)">(iii)</span> The person’s prior record of compliance.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(4)">(4)</span> When the Commission staff determines that a notice of proposed action is not appropriate given the lack of available evidence or other circumstances, it may issue one of the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(4)(a)">(a)</span> A letter advising that no action is recommended at that time; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#C(4)(b)">(b)</span> A letter finding that no action is warranted.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D">D.</span> A person who receives a notice of proposed action from the Commission staff may request an opportunity to show cause why the proposed action should not be taken.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(1)">(1)</span> A written request to show cause shall be filed with the Commission and shall comply with the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(1)(a)">(a)</span> It shall be filed within 20 days of the issuance of the notice of proposed action; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(1)(b)">(b)</span> It shall include each fact upon which the person relies to show cause why the proposed action should not be taken.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(2)">(2)</span> Upon receipt of a request to show cause, the Commission staff may meet with the person to attempt to resolve the matter in a manner that protects the public and is in the public interest.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(3)">(3)</span> If a notice of proposed action is not resolved within 45 days of the filing of a request to show cause, a hearing officer shall be designated by the executive director of the Commission.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(3)(a)">(a)</span> The hearing officer shall hear evidence as needed;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(3)(b)">(b)</span> The hearing shall be conducted in accordance with the Maryland Administrative Procedure Act, <a class="internal-link " href="https://mgaleg.maryland.gov/2023RS/Statute_Web/gsg/gsg.pdf" title="">State Government Article, Title 10, Annotated Code of Maryland</a>, and these regulations.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(3)(c)">(c)</span> The hearing officer shall issue a recommended decision that contains proposed findings of fact and conclusions of law and may recommend that the Commission take one of the following actions:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(3)(c)(i)">(i)</span> Adopt the action proposed by Commission staff;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(3)(c)(ii)">(ii)</span> Adopt a proposed action recommended by the hearing officer; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#D(3)(c)(iii)">(iii)</span> Find that no action is warranted.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#E">E.</span> A request that the Commission not adopt the recommended decision may be made by either Commission staff or a person who is the subject of an enforcement action.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#E(1)">(1)</span> Written exceptions to the recommended decision shall be filed within 20 days of receipt of the hearing officer's recommended decision.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#E(2)">(2)</span> Exceptions shall specifically identify in writing each finding and conclusion to which exception is taken, citing those portions of the record on which each exception is based.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#E(3)">(3)</span> A written response to exceptions to the recommended decision may be filed by an opposing party within 15 days of receipt of exceptions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#E(4)">(4)</span> Each person taking or responding to exceptions may present oral argument to the Commission, not to exceed 10 minutes per party, unless extended by the Chair of the Commission.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#E(5)">(5)</span> The decision of the Commission shall be by a majority of the quorum present and voting.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#F">F.</span> The Commission may coordinate with the Office of Attorney General concerning any potential violation involving a matter within the Attorney General’s authority pursuant to State or federal law.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#G">G.</span> If an HIE has reasonably determined that it is unable to independently meet any requirements of this chapter, then the HIE shall develop and implement policies to ensure the HIE’s compliance through the execution of a written agreement with a participating organization or a business associate that will bring the HIE into compliance with this chapter. Every year as a part of the registration renewal process, the HIE shall submit a written attestation by an independent third-party auditor to the Commission, attesting that the HIE has been in full compliance with the requirements of this chapter for the 12-month period prior to the audit.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H">H.</span> Exemptions.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(1)">(1)</span> An HIE may request a 1-year exemption from certain requirements of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(2)">(2)</span> An exemption request must:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(2)(a)">(a)</span> Be in writing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(2)(b)">(b)</span> Identify each specific requirement of this chapter from which the HIE is requesting an exemption;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(2)(c)">(c)</span> Identify the time period of the exemption, if any;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(2)(d)">(d)</span> State the reason for each exemption request; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(2)(e)">(e)</span> Include information that justifies the exemption request.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(3)">(3)</span> Within 45 days after receipt of complete information from an HIE requesting an exemption, the Commission shall take one of the following actions:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(3)(a)">(a)</span> Grant the exemption by providing written notification; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(3)(b)">(b)</span> Deny the exemption request by providing written notification that enumerates the reasons for the denial to the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(4)">(4)</span> An exemption may not be made for any requirement within this chapter that is otherwise required of the HIE by federal or other State law.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(5)">(5)</span> An exemption may be made on the following grounds:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(5)(a)">(a)</span> The absence of certain functionality in the infrastructure of the HIE that does not allow the HIE to maintain compliance with the requirement;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(5)(b)">(b)</span> The requirement would hinder the ability of the HIE to comply with other requirements of this chapter or federal or other State laws; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(5)(c)">(c)</span> The requirement would cause an undue burden or hardship on the HIE, such that the HIE would no longer be able to provide HIE services in the State.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.09#H(6)">(6)</span> For good cause shown, the Commission may renew a 1-year exemption for an additional 1-year period.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.10" data-order="|10|25|18|.10|" data-ref-path="10|25|18|.10" class="h__section">.10 Requirements for Accessing, Using, or Disclosing of Data Through an HIE for Secondary Use.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#A">A.</span> An HIE may not use or disclose a patient’s sensitive health information for secondary use unless permitted by applicable federal or State laws and regulations.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B">B.</span> Population Health Management.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(1)">(1)</span> An HIE may disclose de-identified data or a limited data set, as defined at 45 CFR §164.514(e), to a care management organization for purposes related to population health management, if approval is obtained from an internal review committee designated by the care management organization, which has:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(1)(a)">(a)</span> Entered into a data use agreement with the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(1)(b)">(b)</span> Attested that the request is:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(1)(b)(i)">(i)</span> For population health management purposes; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(1)(b)(ii)">(ii)</span> Limited to the minimum necessary to complete the function.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(2)">(2)</span> An HIE may disclose individually identifiable health information to a care management organization for purposes related to population health management, if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(2)(a)">(a)</span> The requirements of <a class="internal-link " href="/us/md/exec/comar/10.25.18.10#B(1)" title="">§B(1) of this regulation</a> are met;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(2)(b)">(b)</span> Appropriate notice has been provided to health care consumers whose information is being requested, and either:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(2)(b)(i)">(i)</span> The health care consumers have authorized the release of their information to the requesting entity; or</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(2)(b)(ii)">(ii)</span> An external and independent review committee has waived the need for the requesting entity to obtain authorization from those health care consumers who were provided appropriate notice, in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.02#B(4)" title="">Regulation .02B(4) of this chapter</a>; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(2)(c)">(c)</span> The disclosure is consistent with the authorization.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(3)">(3)</span> Any external and independent review committee identified by the care management organization may approve an authorization waiver request where the requesting care management organization has demonstrated that:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(3)(a)">(a)</span> Appropriate notice to each health care consumer was provided and no authorization or denial of authorization was received from each health care consumer within the 30-day time frame;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(3)(b)">(b)</span> The objectives for which the data was requested could not be met without access to the requested data; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(3)(c)">(c)</span> The requested use or disclosure involves no more than minimal risk to the privacy of those health care consumers whose authorization will be waived based on the presence of attributes that include, at a minimum:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(3)(c)(i)">(i)</span> An adequate plan presented to the external and independent review committee to protect PHI from improper use, storage, and disclosure in accordance with current legal requirements and industry standards and practices as determined by the external and independent review committee;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(3)(c)(ii)">(ii)</span> An adequate plan to destroy the PHI when the purposes for which it has been requested are completed, unless such retention is authorized under the waiver or otherwise required by law; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(3)(c)(iii)">(iii)</span> Adequate written assurances that the PHI will not be reused or disclosed to any person or entity, except as authorized under the waiver, as required or permitted by law, or for authorized oversight of the use.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#B(4)">(4)</span> An HIE may not disclose a patient’s sensitive health information for population health management purposes unless permitted by applicable federal and State laws and regulations.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C">C.</span> Research.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(1)">(1)</span> An HIE may disclose de-identified data to a qualified research organization for research purposes if a privacy board has evaluated and confirmed that the:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(1)(a)">(a)</span> Requesting entity is a qualified research organization; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(1)(b)">(b)</span> Requested data to be disclosed:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(1)(b)(i)">(i)</span> Is for purposes related to research;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(1)(b)(ii)">(ii)</span> Is limited to the minimum necessary to complete the research purpose;</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(1)(b)(iii)">(iii)</span> Will be used to serve a legitimate purpose consistent with the interest of the subject individuals; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(1)(b)(iv)">(iv)</span> Meets the de-identification standard and specifications in accordance with 45 CFR §164.514(a)—(c).</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(2)">(2)</span> An HIE may disclose individually identifiable health information to a qualified research organization for research purposes if:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(2)(a)">(a)</span> Approval is obtained from an IRB or privacy board in accordance with 45 CFR §164.512, including documentation of waiver approval as detailed in 45 CFR §164.512(i)(2); and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(2)(b)">(b)</span> The IRB or privacy board has evaluated the request and confirmed that the requirements of §C(1)(a) and (b)(i)—(iii) of this regulation are met.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(3)">(3)</span> If an IRB or privacy board does not waive or alter the requirement of authorization from health care consumers whose individually identifiable health information is to be disclosed, an HIE may only disclose individually identifiable health information of health care consumers who have provided authorization, which must meet the requirements as set forth in 45 CFR §164.508.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(4)">(4)</span> If an IRB or privacy board declines jurisdiction, then the disclosure of individually identifiable health information may only be made if health care consumer authorization is obtained.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(5)">(5)</span> As part of an HIE’s data use agreement with an entity to which it disclosed individually identifiable health information for secondary use, there shall be oversight by an IRB or privacy board for the duration of the research use.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(6)">(6)</span> If an IRB or privacy board determines that the qualified research organization has failed to use or protect the data in accordance with the approved secondary use, the IRB or privacy board must report its findings to the HIE and the HIE must:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(6)(a)">(a)</span> Report the findings to federal and State agencies with jurisdiction over the violation, as deemed appropriate;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(6)(b)">(b)</span> Immediately terminate the data use agreement; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(6)(c)">(c)</span> Direct the qualified research organization to destroy the data previously released by the HIE and attest that the data has been destroyed.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(7)">(7)</span> The qualified research organization receiving data from an HIE for research purposes:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(7)(a)">(a)</span> Must contractually agree not to attempt to link de-identified data received from the HIE with other data sources in an effort to re-identify the data, or otherwise attempt in any other way to re-identify the data; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(7)(b)">(b)</span> May disclose data to a third party acting on behalf of the qualified research organization only if the qualified research organization and third party enter into a data use agreement that requires the third party to be bound by the same provisions in the data use agreement between the HIE and qualified research organization.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(8)">(8)</span> An HIE may charge a reasonable fee to a qualified research organization to which it discloses data for research, which fee must reflect the effort and be no greater than the actual direct and indirect costs required to prepare and release the data specific to the purpose authorized.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#C(9)">(9)</span> An HIE may not disclose a patient’s sensitive health information for research purposes unless permitted by applicable federal or State laws and regulations.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#D">D.</span> Enforcement and Reporting.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#D(1)">(1)</span> An HIE is not required to take legal or equitable action to enforce the requirements of the data use agreement or of any other contractual assurance provided for in <a class="internal-link " href="/us/md/exec/comar/10.25.18.05#C" title="">Regulation .05C of this chapter</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#D(2)">(2)</span> An HIE shall make summary reports available to the public quarterly that provide specific information about requests for data for secondary use and the release of data for secondary purposes.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#D(3)">(3)</span> An HIE shall report at least annually to the Commission and more frequently, if requested by the Commission, regarding the release of information for population health management. The Commission may:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#D(3)(a)">(a)</span> Require a care management organization to provide additional information for review by the Commission or the Commission’s designated third party regarding the care management organization’s use of data from an HIE for population health management;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#D(3)(b)">(b)</span> Require the HIE to conduct an audit of the disclosure and use of the data utilizing a third-party auditor at the expense of either the recipient of the data or the HIE, as determined by Commission;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#D(3)(c)">(c)</span> Require the receiving entity to destroy the data received and cease any further use of the data; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#D(3)(d)">(d)</span> Prohibit an HIE from releasing data for all or certain secondary data use purposes.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.10#D(4)">(4)</span> An HIE shall, upon the request by a health care consumer, provide an accounting of any disclosures made to a receiving entity for secondary data use purposes, in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#C(4)" title="">Regulation .03C(4) of this chapter</a>.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.11" data-order="|10|25|18|.11|" data-ref-path="10|25|18|.11" class="h__section">.11 Requirements for Accessing, Using, or Disclosing of Data Through an HIE in an Emergency.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#A">A.</span> An HIE shall develop and implement emergency access policies and procedures that satisfy the following requirements:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#A(1)">(1)</span> The policies and procedures shall be included in the HIEs health care consumer education materials required by <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#B(1)" title="">Regulation .03B(1) of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#A(2)">(2)</span> Clearly communicate the following:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#A(2)(a)">(a)</span> The extent to which the HIE has the capability to disclose the patient's information in an emergency and how this compares to disclosure for routine access; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#A(2)(b)">(b)</span> The circumstances under which the HIE would disclose the patient's information in an emergency, including how opting in or out of participation would impact access to the patient's information during an emergency.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B">B.</span> If an HIEs emergency access policy allows the disclosure of information during an emergency, the HIE shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(1)">(1)</span> Only disclose information to the requesting health care provider if the following conditions are met:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(1)(a)">(a)</span> The requesting health care provider:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(1)(a)(i)">(i)</span> Advises the HIE that it is the health care provider's professional opinion that an emergency exists; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(1)(a)(ii)">(ii)</span> Attests that all conditions of the participating organization's policy have been met;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(1)(b)">(b)</span> The patient's condition preclude the participating organization from obtaining the consent of the health care consumer;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(1)(c)">(c)</span> Information available through the HIE may be relevant to the treatment needed by the patient in the specific emergency;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(1)(d)">(d)</span> The participating organization has an established policy that describes the requirements and attestation process for emergency access; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(1)(e)">(e)</span> Disclosure of information available through the HIE is not in violation of applicable federal and State laws and regulations related to sensitive health information.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(2)">(2)</span> Establish technical procedures for documenting an attestation by the requesting health care provider that the conditions in <a class="internal-link " href="/us/md/exec/comar/10.25.18.11#B(1)" title="">§B(1) of this regulation</a>, were met prior to accessing information through the HIE;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(3)">(3)</span> Review the emergency access logs at least monthly, in coordination with the participating organization, to identify any unusual finding;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(4)">(4)</span> Take action in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.06" title=".06 Auditing Requirements.">Regulation .06 of this chapter</a>, in the event the emergency access log reveals an unusual finding;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(5)">(5)</span> Maintain an audit trail of user emergency access logs in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.06#A(8)" title="">Regulation .06A(8) of this chapter</a>; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(6)">(6)</span> Require a participating organization to:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(6)(a)">(a)</span> Access only the minimum necessary information needed to care for the patient during the emergency encounter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(6)(b)">(b)</span> Discontinue querying of the patient's record upon the completion of the emergency encounter;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(6)(c)">(c)</span> Allow emergency access only to authorized users with the appropriate access designation consistent with the policy of the participating organization; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.11#B(6)(d)">(d)</span> Notify the health care consumer, as soon as reasonably possible, and no later than ten business days from the initial access, when the HIE has granted access to the health care consumer's information during an emergency.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.12" data-order="|10|25|18|.12|" data-ref-path="10|25|18|.12" class="h__section">.12 Requirements for Providing Health Care Consumers Electronic Access to Their Health Information.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A">A.</span> An HIE or its third party that offers health care consumers electronic access to view, download, transmit, submit, or control their health information shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(1)">(1)</span> Appropriately verify the identity of the health care consumer requesting electronic access or proposing an addition or change to the patient’s information available through the HIE prior to disclosing or accepting changes to the information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(2)">(2)</span> Follow, at a minimum, the National Institute of Standards and Technology (NIST) Level 2 registration and identity proofing requirements as outlined in the most recent version of Special Publication 800-63: Electronic Authentication Guideline or its comparable industry best practices and may perform remote identity proofing;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(3)">(3)</span> Implement the health care consumer’s authorization for access within a maximum of 5 business days of receipt of all necessary information for identity proofing;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(4)">(4)</span> Adopt and implement authentication processes for health care consumer electronic access that is in accordance with Regulation .05D(3) and (4) of this chapter;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(5)">(5)</span> Establish individual unique user names and passwords in accordance with the most recent applicable standards issued by NIST, or other comparable standards generally adopted by the health care and HIE industry;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(6)">(6)</span> Implement processes for auditing health care consumer access that are in compliance with applicable requirements of <a class="internal-link " href="/us/md/exec/comar/10.25.18.06" title=".06 Auditing Requirements.">Regulation .06 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(7)">(7)</span> Implement a process for suspending and reinstating a health care consumer’s access in compliance with applicable requirements in <a class="internal-link " href="/us/md/exec/comar/10.25.18.07" title=".07 Remedial Actions to Be Taken by an HIE.">Regulation .07 of this chapter</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(8)">(8)</span> Establish processes and procedures to allow a patient to authorize an individual to have electronic access to their information;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(9)">(9)</span> Establish processes and procedures that allow an individual to electronically access health information for a patient or patients:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(9)(a)">(a)</span> For whom the individual has legal authorization for such access (e.g., guardian, person with a medical power of attorney, etc.); or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(9)(b)">(b)</span> For whom the patient has authorized such access;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(10)">(10)</span> Establish processes and procedures to confirm the authority of a person in interest, if not directly authorized by a patient, which must be satisfied as a condition to providing access to that person in interest; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#A(11)">(11)</span> Comply with applicable federal and State laws and regulations related to sensitive health information when disclosing such information to a health care consumer.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#B">B.</span> An HIE or its third party that offers health care consumers electronic access to view, download, transmit, submit, or control their information may:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#B(1)">(1)</span> Charge a reasonable cost-based published fee for healthcare consumer electronic access consistent with applicable federal and State laws; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#B(2)">(2)</span> Deny a health care consumer’s electronic access in accordance with:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#B(2)(a)">(a)</span> Applicable law or regulation, including 45 CFR §164.524, in coordination with applicable participating organizations; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#B(2)(b)">(b)</span> The HIE’s reasonable policies, procedures, or agreements with a participating organization and shall provide notice to the health care consumer of their right to request access to the patient’s health information from the covered entity.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C">C.</span> An HIE or its third party that offers health care consumer electronic access to view the patient’s health information available through the HIE shall, in accordance with federal and State law:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(1)">(1)</span> Provide the patient’s health information that is equivalent to what is made available to authorized users that are health care providers, which may include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(1)(a)">(a)</span> Demographic information, such as name, address, and date of birth;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(1)(b)">(b)</span> Provider encounters or procedures performed (e.g., hospital, ambulatory, post-acute care, etc.);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(1)(c)">(c)</span> Immunizations;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(1)(d)">(d)</span> Visit summaries;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(1)(e)">(e)</span> Care plan(s);</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(1)(f)">(f)</span> Clinical test results; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(1)(g)">(g)</span> Prescriptions;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(2)">(2)</span> At a minimum, and if made available through the HIE, make the following data attributes for the patient’s health information electronically available to the health care consumer:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(2)(a)">(a)</span> Date of the encounter, procedure, test, prescription, or immunization;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(2)(b)">(b)</span> Results or summary of the encounter, procedure, test, prescription, or immunization; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(2)(c)">(c)</span> Source of the health information, including provider name and organization name;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(3)">(3)</span> Inform health care consumers regarding:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(3)(a)">(a)</span> Contacting their health care provider to discuss the health information they may be viewing if they have any concerns or questions; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(3)(b)">(b)</span> Translation services and resources that may be available, through the HIE or another entity, to help assist the health care consumer in understanding their health information; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(4)">(4)</span> Allow the health care consumer to view the patient’s health information in an electronic format that meets the following criteria:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(4)(a)">(a)</span> The information is presented in substantially the same form and format as presented to an authorized user that is a health care provider;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(4)(b)">(b)</span> The form and format presented to a health care consumer is easy for the health care consumer to navigate;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(4)(c)">(c)</span> The information can be easily printed; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#C(4)(d)">(d)</span> If supplemental information is made available along with the patient’s health information, such as educational resources, the supplemental information meets the criteria specified in Regulation .03B(2)(c)—(e) of this chapter.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#D">D.</span> An HIE or its third party that offers health care consumers the ability to electronically control the patient’s health information being made available through the HIE shall:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#D(1)">(1)</span> Implement technology processes that meet industry standards and best practices and are in compliance with State and federal privacy and security laws; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#D(2)">(2)</span> Provide an electronic process by which a health care consumer can control the patient’s health information that is in accordance with §C(4)(b)—(d) of this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#E">E.</span> An HIE or its third party that offers health care consumers the ability to download the patient’s health information being made available through the HIE shall provide the patient’s health information that is:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#E(1)">(1)</span> In accordance with §C(3) and (4)(b)—(d) of this regulation;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#E(2)">(2)</span> Requested by the health care consumer; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#E(3)">(3)</span> In a readily available industry standard format.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#F">F.</span> An HIE or its third party that offers health care consumers the ability to submit information to the HIE:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#F(1)">(1)</span> Shall identify the source of the information, such as patient, payor, or health care provider, when presented to an authorized user of the HIE; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#F(2)">(2)</span> May not use patient submitted health information to override or replace health information submitted from other sources.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#G">G.</span> An HIE or its third party that offers health care consumers the ability to transmit the patients’ health information being made available through the HIE to a third party of the health care consumer’s designation shall comply with the requirements as detailed in:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#G(1)">(1)</span> <a class="internal-link " href="/us/md/exec/comar/10.25.18.12#C(3)" title="">§C(3) of this regulation</a>;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#G(2)">(2)</span> §C(4)(b) and (d) of this regulation; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#G(3)">(3)</span> <a class="internal-link " href="/us/md/exec/comar/10.25.18.12#E(2)" title="">§E(2) of this regulation</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#H">H.</span> Health Care Consumer Education About Electronic Access.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#H(1)">(1)</span> An HIE shall provide needed information, as part of its health care consumer education plan (as detailed in .03B(1) of this chapter and meeting the characteristics as detailed in <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#B(2)" title="">Regulation .03B(2) of this chapter</a>), about the services or features offered by the HIE or its third party that allows the health care consumer to electronically view, download, submit, or control the patient’s information that is available through the HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#H(2)">(2)</span> The health care consumer education plan shall outline the process which, if available, allows a health care consumer to electronically view, download, transmit, submit, or control the patient’s information that is available through the HIE, including:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#H(2)(a)">(a)</span> The information the health care consumer must provide as part of patient identity proofing;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#H(2)(b)">(b)</span> The patient’s rights to:</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#H(2)(b)(i)">(i)</span> Authorize a person in interest or individual to also have access to the patient’s health information; and</p>
                <p class="text-indent-4 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#H(2)(b)(ii)">(ii)</span> Request a review of a denial of access;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#H(2)(c)">(c)</span> The extent to which the health care consumer has control of the patient’s health information being made available through the HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.12#H(2)(d)">(d)</span> The need to safeguard information obtained from the HIE to the same extent they safeguard other sensitive personal information.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.13" data-order="|10|25|18|.13|" data-ref-path="10|25|18|.13" class="h__section">.13 Noncontrolled Prescription Drugs Dispenser Reporting.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#A">A.</span> For each noncontrolled prescription drug dispensed, the dispenser shall report drug information to the State-designated HIE in accordance with this regulation.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B">B.</span> MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(1)">(1)</span> The Commission shall develop a MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(2)">(2)</span> The Commission shall approve a MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual by June 1 of each year to be used for reporting by the last business day of September of the same calendar year.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(3)">(3)</span> The MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual shall minimally:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(3)(a)">(a)</span> Specify the data and prescription drug information that must be submitted by dispensers to the State-designated HIE in accordance with this regulation, including specifying the American Society for Automation in Pharmacy (ASAP) standard;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(3)(b)">(b)</span> Specify the timeframe and frequency of data submissions to the State-designated HIE;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(3)(c)">(c)</span> Require a dispenser to report data elements consistent with the ASAP standard identified in MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(3)(d)">(d)</span> Include electronic reporting specifications, encryption algorithms, file layout, and the process for dispensers who are unable to submit data due to mechanical, electrical, or other technical failure; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(3)(e)">(e)</span> Align, to the extent possible, with the Maryland Prescription Drug Monitoring Program Data Submitter User Guide.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(4)">(4)</span> The Commission shall publish a draft Noncontrolled Prescription Drugs Dispenser Data Submission Manual on the Commission’s website and in the Maryland Register at least 30 days before the public meeting at which the Commission shall consider the manual for final approval and provide at least 20 days for the submission of public comment.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(5)">(5)</span> The Commission shall consider all comments received before final approval of the Noncontrolled Prescription Drugs Dispenser Data Submission Manual.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(6)">(6)</span> The Commission shall publish the final MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual on its website within  5 days of its approval.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(7)">(7)</span> The State-designated HIE shall post a link to MHCC’s Noncontrolled Prescription Drugs Dispenser Data Submission Manual prominently on its website.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(8)">(8)</span> The Commission may correct incomplete or erroneous information in the MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual as necessary and shall provide notice of each correction:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(8)(a)">(a)</span> On its website; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#B(8)(b)">(b)</span> By email to the designated dispenser contact person.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#C">C.</span> Means of Data Submission and Data Format.  A dispenser shall transmit noncontrolled prescription drug information to the State-designated HIE:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#C(1)">(1)</span> Consistent with the requirements detailed in the most recent version of the MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#C(2)">(2)</span> By use of an encrypted electronic transmission method or a secure electronic reporting form; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#C(3)">(3)</span> In a format or utilizing data standards approved by the Commission.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#D">D.</span> Reporting Deadline.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#D(1)">(1)</span> Unless granted a waiver under <a class="internal-link " href="/us/md/exec/comar/10.25.18.13#F" title="">§F of this regulation</a>, a dispenser shall report to the State-designated HIE:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#D(1)(a)">(a)</span> The noncontrolled prescription drug information required by the MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual no later than the end of the next day of operation after the prescription is dispensed; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#D(1)(b)">(b)</span> A zero report no later than the end of the next day of operation after a day without dispenses of noncontrolled prescription drugs.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#D(2)">(2)</span> A dispenser that suffers a mechanical, electrical, or other technical failure that, as a direct consequence, precludes the dispenser’s ability to report non-controlled prescription data electronically shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#D(2)(a)">(a)</span> Notify the State-designated HIE by a communication method approved by the State-designated HIE within 24 hours of discovery of the technical failure; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#D(2)(b)">(b)</span> Submit a report for each noncontrolled prescription drug dispensed during the period of technical failure as soon as possible, but no later than 24 hours following reestablishment of the means of electronic reporting.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E">E.</span> Acceptance and Disclosure of Noncontrolled Prescription Drug Information by the State-designated HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E(1)">(1)</span> The State-designated HIE shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E(1)(a)">(a)</span> Electronically collect noncontrolled prescription drug information from dispensers;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E(1)(b)">(b)</span> Not impose any fees or other assessments on dispensers to support its operation;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E(1)(c)">(c)</span> Make information technology available for dispensers to report noncontrolled prescription drug information to the State-designated HIE; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E(1)(d)">(d)</span> Retain noncontrolled prescription drug information collected pursuant to this section for at least 5 years from the date of receipt, except for the PHI of patients who opt-out of an HIE consistent with Regulation.03 of this chapter.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E(2)">(2)</span> The State-designated HIE may reject data submitted by dispensers that does not comply with the requirements of the MHCC Noncontrolled Prescription Drugs Dispenser Data Submission Manual.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E(3)">(3)</span> If the State-designated HIE rejects the data submitted by a dispenser, the dispenser shall correct and resubmit the data no later than 7 business days after receiving notification from the State-designated HIE of receipt of incomplete or inaccurate data.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E(4)">(4)</span> Beginning January 1, 2026, the State-designated HIE shall make patient-specific prescription information submitted by dispensers under this section available for purposes allowed under applicable law.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#E(5)">(5)</span> Upon written request for public health purposes and as allowed by applicable law, the State-designated HIE shall provide data collected under this regulation within 5 days to the Maryland Department of Health, local health departments, the Commission, or the Health Services Cost Review Commission.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F">F.</span> Dispenser Waiver Request Process.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(1)">(1)</span> Prior to September 1, 2025, dispensers of noncontrolled prescription drug information are exempt from reporting dispensed information to the State-designated HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(2)">(2)</span> A dispenser that dispenses noncontrolled prescription drugs may seek a waiver from the Commission of the requirements in this regulation based on:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(2)(a)">(a)</span> Economic hardship;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(2)(b)">(b)</span> Technology limitations that are not reasonably within the dispenser’s control;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(2)(c)">(c)</span> Dispensing less than 100 noncontrolled prescription drugs annually; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(2)(d)">(d)</span> Other circumstances determined by the Commission to be extenuating.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(3)">(3)</span> A request for a waiver shall be in writing and shall include:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(3)(a)">(a)</span> A detailed explanation of the need for the waiver;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(3)(b)">(b)</span> An attestation as to the accuracy of the information in the waiver request; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(3)(c)">(c)</span> An attestation that the dispenser shall immediately inform the Commission if the circumstances necessitating a waiver no longer exist.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(4)">(4)</span> Within 45 days after receipt of complete information from a dispenser requesting a waiver, the Commission shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(4)(a)">(a)</span> Grant a time-limited waiver request; or</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(4)(b)">(b)</span> Deny the waiver request, with an explanation that enumerates the reasons for the denial.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.13#F(5)">(5)</span> A dispenser shall inform the Commission and immediately begin reporting in compliance with this regulation if the dispenser no longer meets the conditions of a waiver request.</p>
                <hr class="section-separator" aria-hidden="true"/>
                <h2 id="/us/md/exec/comar/10.25.18.14" data-order="|10|25|18|.14|" data-ref-path="10|25|18|.14" class="h__section">.14 Operation of the State-designated HIE as a Health Data Utility.</h2>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#A">A.</span> The State-designated HIE shall operate as a health data utility for the State.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#B">B.</span> The State-designated HIE shall implement a consent management application in accordance with <a class="internal-link " href="/us/md/exec/comar/10.25.18.03#D" title="">Regulation .03D of this chapter</a>.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#C">C.</span> Disclosures by the State-designated HIE.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#C(1)">(1)</span> Except as otherwise prohibited under this chapter or State or federal law, the State-designated HIE shall transmit clinical information or electronic health care transactions to the Maryland Department of Health, the Commission, or the Health Services Cost Review Commission for public health purposes upon written request.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#C(2)">(2)</span> The State-designated HIE may not redisclose financial information in electronic health care transactions it receives in accordance with <a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.07.09" title=".09 Electronic Health Network Transaction Submission.">COMAR 10.25.07.09</a> to any person other than the Commission.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#C(3)">(3)</span> Maryland Medical Care Data Base.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#C(3)(a)">(a)</span> The State-designated HIE shall be designated as a reporting entity to the Maryland Medical Care Data Base.</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#C(3)(b)">(b)</span> The State-designated HIE shall report the electronic health care transactions information it receives pursuant to <a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.07.09" title=".09 Electronic Health Network Transaction Submission.">COMAR 10.25.07.09</a> to the Medicare Care Data Base in accordance with the reporting requirements found in <a class="internal-link no-wrap" href="/us/md/exec/comar/10.25.06" title="Chapter 06 Maryland Medical Care Data Base and Data Collection">COMAR 10.25.06</a>.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#C(4)">(4)</span> The State-designated HIE shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#C(4)(a)">(a)</span> Develop a process in which requests for data are submitted and data are shared, and post this information on its website; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#C(4)(b)">(b)</span> Provide a written explanation for a denial of a request which shall include an appeal process.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#D">D.</span> The State-designated HIE shall consult with the Maryland Department of Health, the Commission, and Health Services Cost Review Commission before identifying any specific purposes, type of data exchanged, and rules for interaction between users and the State-designated HIE pertaining to:</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#D(1)">(1)</span> A State health improvement program;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#D(2)">(2)</span> Mitigation of a public health emergency;</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#D(3)">(3)</span> Improvement of patient safety; and</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#D(4)">(4)</span> Any other public health priorities identified by the Secretary.</p>
                <p class="text-indent-1 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#E">E.</span> Consumer Advisory Council.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#E(1)">(1)</span> The State-designated HIE shall establish a Consumer Advisory Council in accordance with Health-General Article, §19-145, Annotated Code of Maryland.</p>
                <p class="text-indent-2 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#E(2)">(2)</span> The State-designated HIE shall:</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#E(2)(a)">(a)</span> Appoint two consumer representatives identified by the Commission who have significant experience in public health and patient privacy as council members;</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#E(2)(b)">(b)</span> Post advance notice of council meetings on its website, including an expected agenda; and</p>
                <p class="text-indent-3 "><span class="level-num" id="/us/md/exec/comar/10.25.18.14#E(2)(c)">(c)</span> Require the Consumer Advisory Council to comply with the requirements of the Maryland Open Meetings Act as if it were a public body.</p>
                <hr class="section-separator" aria-hidden="true"/>
              </div>
            </article>
          </main>
          <nav id="area__navigation_mini" class="ns__document__maryland-dsd" aria-label="Previous and next article links">
            <section>
              <a href="/us/md/exec/comar/10.25.17" aria-label="Chapter 17 Benchmarks for Preauthorization of Health Care Services">
                <div class="h__ui">Previous</div>
                <span>Chapter 17 Benchmarks for Preauthorization of Health Care Services</span>
              </a>
            </section>
            <section>
              <a href="/us/md/exec/comar/10.25.19" aria-label="Chapter 19 State Recognition of an Electronic Advance Directives Service">
                <div class="h__ui">Next</div>
                <span>Chapter 19 State Recognition of an Electronic Advance Directives Service</span>
              </a>
            </section>
          </nav>
        </div>
      </div>
      <footer id="section__footer" class="ns__document__maryland-dsd">
        <div id="section__footer__inner" class="ns__document__maryland-dsd">
          <div id="area__footer__content" class="ns__document__maryland-dsd">
<p>This version of the laws and codes on this website is licensed under the <a href="https://creativecommons.org/licenses/by-nc-sa/4.0/">CC BY-NC-SA 4.0</a> license with copyright held by the State of Maryland.</p><p>This version of the laws and codes on this website will be dedicated to the public domain under the <a href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 1.0</a> license 180 days after publication.</p>
<p>
      Please do not scrape. Instead, bulk download the CC BY-NC-SA-4.0 <a href="https://github.com/maryland-dsd/law-html">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml">XML</a> or CC0 <a href="https://github.com/maryland-dsd/law-html-cc0">HTML</a> or <a href="https://github.com/maryland-dsd/law-xml-cc0">XML</a>.
    </p><p>Powered by the non-profit <a href="https://www.openlawlib.org/">Open Law Library</a>.</p></div>
        </div>
      </footer>
    </div>
    <!--Piwik analytics-->
    <noscript>
      <img src="/_analytics/pixel.png" style="border:0;" alt=""/>
    </noscript>
  </body>
</html>
